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ABSTRACT
The primary aims of the current study were to examine if smoking expectancies and readiness to
quit smoking, important components in predicting smoking behavior and cessation, changed
across time for adult smokers in substance use treatment. Participants (N = 51) were
predominantly white (96.1%), adult, male smokers who were admitted to residential substance
use treatment. Smoking outcome expectancies and readiness to change smoking were assessed
among participants at treatment entry (n = 51), and subsequently at 30 days (n = 13), 60 days (n
= 9), and 90 days (n = 3) from treatment entry. Ninety-day follow-up assessments were excluded
from outcome analyses due to significant participant attrition. At baseline, the majority of
participants were in the contemplation (40%) or preparation (action) (40%) stage of change for
smoking cessation. Repeated measures analyses of variance (ANOVAs) revealed a significant
decrease in health risk and negative affect reduction smoking expectancies across time points.
Readiness to change smoking did not significantly differ across time points. Existing literature
on smoking expectancies has shown that elevated health risk beliefs predict cessation treatment
entry, whereas elevated expectations for negative affect reduction predict relapse after a
cessation attempt. Findings in the current study suggest that manipulation of health risk
expectancies at treatment entry may increase engagement in a subsequent cessation attempt. In
addition, negative affect reduction expectancies may change with the acquisition of alternate
skills to manage negative affect learned in substance use treatment. Although readiness to change
smoking did not increase over time in substance use treatment, the majority of smokers at
baseline were already in the contemplation and preparation stages for quitting smoking. Based on
the current findings, the optimal time for smoking cessation intervention efforts may be between
30 to 60 days after entering substance use treatment.
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INTRODUCTION
Overview of Smoking
Smoking is the leading cause of preventable death in the United States (U.S.), with
approximately 480,000 deaths each year due to smoking-related causes (USDHHS, 2014).
Within the last five decades, over 20 million people have died from tobacco-related illnesses in
the U.S. (USDHHS, 2014). Numerous diseases and health problems are associated with smoking
and approximately 300 billion dollars per year are lost in the U.S. due to health care
expenditures/ loss of productivity related to smoking (USDHHS, 2014). Strategies in the U.S.
have been employed to reduce smoking prevalence, including increased anti-smoking
advertisements, access to cessation interventions, and taxes on cigarettes (USDHHS, 2014).
Even though smoking rates in the U.S. have decreased significantly over the past 20 years,
differences are present among subgroups of smokers. Individuals in substance use treatment
smoke at much higher rates than the general population (USDHHS, 2014; Ward, Kedia, Webb,
& Relyea, 2012). Further, among substance abusers, tobacco-related deaths are considerably
higher when compared to the general population (Bandiera, Anteneh, Le, Delucchi, & Guydish,
2015). Therefore, researchers need to identify ways to effectively reduce smoking prevalence
among individuals in substance use treatment.
Substance Use and Tobacco Mortality
Tobacco and substance use both independently contribute to the development of
psychological and physiological diseases (Grant et al., 2016; Lim et al., 2012; USDHHS, 2014;
Walker, Pratt, Schoenborn, & Druss, 2017). However, when tobacco and substance use occur
comorbidly, the combination of the two disorders creates additional psychological and
physiological conditions, and their comorbid occurrence places the individual at significant risk
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for premature mortality. Hser, McCarthy, and Anglin (1994) conducted a longitudinal study in
which they examined mortality rates for patients receiving substance use treatment and found
that the death rate of smokers was four times more than that of nonsmokers at a 20-year followup. Hurt et al. (1996) conducted a retrospective study in which they examined mortality rates and
causes of death among those receiving addiction treatment. It was determined that patients in
addiction treatment were significantly more likely to die of tobacco-related causes rather than
alcohol (Hurt et al., 1996). While the abuse of alcohol and licit/illicit substances may have more
apparent short-term consequences than smoking, substance abusers who smoke are at an
increased risk of dying from tobacco-related complications than from the substance for which
they are seeking treatment (Hser et al., 1994; Hurt et al., 1996).
Oregon death records analyzed from 1999 to 2005 for the general population (e.g., those
without any reported substance abuse or mental health problems) highlighted the alarming
mortality statistics for substance abusers who smoke. Bandiera et al. (2015) examined 148,761
death records in Oregon occurring between 1999 and 2005 in which a physician completed a
certificate stating whether the role of tobacco was involved in the death. Bandiera et al. (2015)
identified three distinct categories within the sample of deceased individuals: the general
population (no mental health history of diagnoses), those with substance abuse problems, those
with mental health problems, and those with both substance abuse and mental health problems.
Of the reported deaths in which the cause of death was known to be tobacco-related or not,
30.7% of deaths in the general population were attributable to tobacco, 30% of deaths in the
mental health population were attributable to tobacco, 53.6% of deaths in the substance abuse
population were attributable to tobacco, and 46.8% of deaths in the dual substance abuse and
mental health problems population were attributable to tobacco (Bandiera et al., 2015). Further
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analyses revealed that males and females in the substance abuse or dual problem group were
significantly more likely to die from tobacco-related illnesses compared to the general population
or those with just mental health problems. Tobacco-related deaths were found to occur more
frequently at earlier ages (59 years of age and below) among those with substance abuse
problems, mental health problems, and dual problems. However, for ages 60-69, the trend among
tobacco-related deaths in these subgroups occurred at similar rates when compared to the general
population. The high smoking prevalence among substance abusers, as well as the significantly
increased rates of mortality due to comorbid substance abuse and tobacco use, has compelled
investigations on how to effectively reduce smoking within this population.
Cessation Programs in Substance Use Treatment Settings
An association between continued smoking and craving/use of other substances has been
documented within the literature. Among individuals with remitted alcohol use disorder, those
identified as smokers at a 3-year follow-up were significantly more likely to report relapse to
alcohol abuse or dependence than nonsmokers (Weinberger, Platt, Jiang, & Goodwin, 2015).
Recent smoking and decreased confidence to stop smoking have been found to be predictive of
drinking relapse among patients in concurrent substance abuse and tobacco cessation treatment
(Holt, Litt, & Cooney, 2012). Research has also highlighted the association between increased
smoking frequency and increased craving for cocaine and dual craving of cocaine and heroin
among methadone-maintained outpatients (Epstein, Marrone, Heishman, Schmittner, & Preston,
2010). A meta-analysis investigating the relationship between cannabis and tobacco identified an
association between tobacco use in substance abuse treatment and a decreased likelihood of
abstinence from cannabis (Peters, Budney, & Carroll, 2012). Research also supports that
resuming or starting to smoke after entering substance abuse treatment is associated with
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decreased rates of abstinence for the substance in which treatment was initially sought. At a 12month follow-up, patients in substance abuse treatment who quit smoking or who were
nonsmokers tended to report more days abstinent from substances other than tobacco compared
to those who remained smoking or those who resumed/ started smoking (Kohn, Tsoh, &
Weisner, 2003). These findings indicate a greater risk of relapse on licit/illicit substances among
patients who begin to smoke, or lapse, after starting substance abuse treatment (Kohn et al.,
2003).
Given the associations identified between continued smoking and increased cravings/
decreased rates of abstinence for other substances among those in substance use treatment, there
have been efforts made to include smoking cessation within substance use treatment settings.
Thurgood, McNeill, Clark-Carter, and Brose (2016) conducted a meta-analysis examining the
effectiveness of smoking cessation interventions for adults in substance use treatment or
recovery. Specifically, they looked at 17 randomized controlled trials (RCTs) that included
biochemically verified abstinence from smoking at either 6- or 12-month follow-up with
substance use treatment outcomes included as a secondary aim. Thurgood et al. (2016) identified
eight alcohol only treatment studies, five alcohol and drug treatment studies, and four drug only
treatment studies that included an RCT for smoking cessation conducted from 1990 to 2014. Out
of these 17 identified studies, 5 reported significant effects of smoking cessation (e.g., nicotine
replacement therapy, behavioral support, and combination) at 6- or 12-month follow-up on
reducing smoking rates for smokers in substance use treatment. The combination of cognitivebehavioral therapy, nicotine patch, and nicotine gum was found to produce the highest cessation
rates at 12-month follow-up when compared to any of these treatments alone or a placebo gum
condition. Two studies in which smoking cessation included contingency management (i.e.,
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providing monetary incentives in exchange for biochemically verified abstinence) and relapse
prevention also showed improvements in substance use outcomes. Lastly, none of the 17 studies
within this meta-analysis reported that smoking cessation adversely affected substance use
outcomes. These findings are inconsistent with common clinical lore that smoking cessation
should be discouraged during treatment for substance use disorders, as it may place patients at
risk for early relapse to their drug of choice. Many substance abuse staff maintain the view that
coinciding change of both disorders may be too challenging for the individual to cope with at one
time (Walsh, Bowman, Tzelepis, & Lecathelinais, 2005).
Bernstein and Stoduto (1999) conducted one of the first studies in which a smoking
cessation program was implemented in a substance use treatment context, and that addressed
staff acceptability of such a program. The study also assessed client and staff attitudes toward a
smoking cessation program and motivation to quit smoking within the stages of change (J. O.
Prochaska, Norcross, & DiClemente, 1994). Bernstein and Stoduto (1999) administered a
choice-based smoking cessation program for staff and clients within a substance use treatment
center. The staff at the facility, along with the researchers, developed the program so that the
staff became more knowledgeable about tobacco use and more motivated to introduce a
cessation program into their treatment setting. The program consisted of a smoking cessation
awareness component (i.e., education about smoking and smoking/ substance use recovery)
followed by an available cessation program. The facility was smoke-free, but had designated
smoking areas on the campus. A majority of staff (98.2%) and clients (87.0%) reported that a
smoking cessation program within substance use treatment would be a good idea. However, both
staff and clients also reported that banning smoking from the facility would be problematic
(Bernstein & Stoduto, 1999). Fifty five point 6% of staff and 38% of clients who smoked entered
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the cessation program (Bernstein & Stoduto, 1999). Of the clients who participated in the
cessation program and chose cessation as an end goal (vs. smoking reduction), 17.5% reported
not smoking in the past 7 days, at the 6-month or 1-year follow-up. Among clients who engaged
in the cessation program, a greater proportion reported progression versus regression in readiness
to quit smoking (Bernstein & Stoduto, 1999). Disseminating educational information regarding
smoking and smoking/ substance abuse among staff and clients may alter attitudes towards the
inclusion and utilization of cessation in substance use treatment.
Past research has identified an underlying ambivalence towards cessation among smokers
in substance use treatment (Asher et al., 2003; Richter, Hunt, Cupertino, Garrett, & Friedmann,
2012). As a result, one variable of interest in addressing smoking cessation for those with
substance use disorders is how to increase the likelihood of patients utilizing available smoking
cessation services. Guydish et al. (2016) conducted a study in which they sought to determine
how the inclusion of a readiness group, or a readiness group with the inclusion of contingency
management, affected rates of attending an available smoking cessation program among smokers
in substance abuse treatment. The readiness group consisted of personalized feedback, didactic
presentations, skills training personalized to the stage of change, and a facilitated personalized
quit attempt with access to nicotine replacement therapy, while the contingency management
group also included financial incentives. Guydish et al. (2016) determined that the inclusion of
financial incentives did not increase the likelihood of a patient utilizing smoking cessation
services. Rather, motivation and quitting rehearsal were predictive of a patient utilizing services
provided. Furthermore, Guydish et al. (2016) found that after completing the readiness group,
smokers significantly decreased their daily smoking rate and significantly lowered their nicotine
dependence level from baseline. While contingency management is an effective method for
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increasing abstinence in substance use populations (Higgins, Silverman, & Heil, 2007), Guydish
et al. (2016) concluded that financial incentives might not be as important as pre-cessation
motivational enhancement for smokers in substance abuse treatment. Nevertheless, these
findings provide evidence that personalized motivational enhancement interventions can
manipulate ambivalence towards cessation among smokers in substance abuse treatment.
Other research has sought to determine the effect of contingency management on
smoking cessation for those in substance use treatment. Robles et al. (2005) utilized contingency
management in a smoking cessation program for women in residential substance use treatment.
Patients completed biochemically verified measures of smoking at 1-week pre-quit, through 4weeks of a cessation program, and then again at 2-weeks post-intervention. Patients submitted
significantly more negative biochemically verified samples for smoking abstinence during the
intervention compared to the pre-quit week. However, the effects were no longer significant at 2
weeks post-intervention. Robles et al. (2005) reported that participants in their study were
administered bupropion to manage comorbid depression. While bupropion has been found to
improve cessation outcomes, the effects of other pharmacological treatments found to be
efficacious (e.g., nicotine replacement therapy) for treating nicotine dependence were not made
available to participants (Robles et al., 2005). Other research has documented that among
substance users in treatment, those who successfully quit smoking reported using a combination
of strategies including prayer, nicotine gum, behavioral and cognitive coping strategies, and
nicotine fading (gradual reduction in daily smoking rate) (Richter, McCool, Okuyemi, Mayo, &
Ahluwalia, 2002). Research has determined that among other populations utilizing contingency
management in combination with usual care (i.e., pharmacological treatment and counseling) is
significantly efficacious in producing prolonged abstinence from smoking. Kendzor et al. (2015)
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found that low socioeconomic smokers receiving contingency management in addition to usual
care were significantly more likely to be abstinent from smoking at a 12-week post quit followup compared to those receiving usual care only. In conclusion, the findings of Robles et al.
(2005) suggest that contingency management alone may be helpful as a component of smoking
cessation for smokers in substance use treatment, but that other components of cessation
treatment (e.g., pharmacological and counseling) may be needed to produce lasting change.
Joseph, Willenbring, Nugent, and Nelson (2004) conducted a clinical trial looking at the
long-term effects of a delayed (6-months) versus concurrent smoking cessation intervention for
patients in alcohol dependence treatment. While long-term smoking rates were comparable
between both groups at the 18-month follow-up, there were significant differences in alcohol use
among groups. Specifically, those in the concurrent interventions had significantly lower alcohol
abstinence rates at 6, 12, and 18-month follow-ups compared to those in the delayed intervention
condition (Joseph et al., 2004). The findings of Joseph et al. (2004) provide some evidence that a
delayed smoking cessation intervention may be better for long-term alcohol outcomes, but
inconsequential in long-term smoking abstinence. Kalman et al. (2001) compared the long-term
effects of a delayed (6-week) versus concurrent smoking cessation intervention for male smokers
in substance abuse treatment. The delayed versus concurrent intervention did not yield
significantly different outcomes on tobacco abstinence at final follow-up. Collectively, these
studies indicate that the timing of cessation interventions for smokers in substance abuse
treatment may be relevant to the successful cessation of both smoking and substance use
disorders.
Smoking Expectancies
Outcome expectancies, the anticipated reinforcing and punishing effects of a substance
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play an important role in the initiation, maintenance, and cessation of substance use and smoking
(Bot, Engels, & Knibbe, 2005; Brandon, Juliano, & Copeland, 1999; Jones, Corbin, & Fromme,
2001; Leventhal & Schmitz, 2006). A sizeable literature has established smoking outcome
expectancies as predictive of smoking motivation and consumption, nicotine dependence levels,
motivation to quit smoking, and cessation outcomes (Brandon & Baker, 1991; Copeland,
Brandon, & Quinn, 1995; Heinz, Kassel, Berbaum, & Mermelstein, 2010). Indeed, in several
studies, expectancies have been targeted for change as an intervention strategy for behavior
change related to both smoking and alcohol use (Copeland & Brandon, 2000; Darkes &
Goldman, 1998). Brandon and Baker (1991) developed the Smoking Consequences
Questionnaire (SCQ) to assess smoking expectancies among college students and identified four
factor-analytically derived, reliable factors named—Negative Consequences (e.g., health risk,
addiction sustainment, respiratory irritation, and negative social impression), Positive
Reinforcement-Sensory Satisfaction (e.g., taste, sensorimotor manipulation, social facilitation,
positive affect), Negative Reinforcement-Negative Affect Reduction (e.g., anxiety reduction,
anger/irritability reduction, depression reduction), and Appetite-Weight Control. In the study,
daily smokers reported higher positive reinforcement and negative reinforcement expectancies
compared to occasional smokers, ex-smokers, triers, and those who had never smoked. In a
subsequent study using the SCQ with adult, heavy smokers with considerable smoking
experience and high levels of nicotine dependence Copeland et al. (1995) identified ten distinct,
reliable factors and named the revised measure the SCQ-Adult (SCQ-A). The ten factors were
named Negative Affect Reduction, Stimulation/State Enhancement, Health Risks, Taste/
Sensorimotor Manipulation, Social Facilitation, Appetite-Weight Control, Craving
Reduction/Addiction, Negative Physical Feelings, Boredom Reduction, and Negative Social
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Impression. Copeland et al. (1995) reported that with increased smoking experience, smoking
expectancies become more refined and crystalized, consistent with expectancy theory (Goldman,
Brown, Christiansen, & Smith, 1991).
Research has been conducted to determine which expectancies are predictive of cessation
attempts, successful cessation, and relapse prevention. Lower negative affect reduction
expectancies and higher health risk expectancies have been found to predict quit attempts and
successful cessation (Copeland et al., 1995; McCaul et al., 2006; Rose, Chassin, Presson, &
Sherman, 1996; Wetter et al., 1994). Rose et al. (1996) conducted a longitudinal study with
young adult smokers and found that higher health consequence beliefs about smoking predicted
quit attempts among heavy smokers. Furthermore, higher value of health was associated with
successful cessation (Rose et al., 1996). McCaul et al. (2006) conducted a meta-analysis
examining studies that identified motives to quit smoking among current smokers, ex-smokers,
and smokers currently in a cessation program. Smoking-related health consequence beliefs were
consistently reported as a primary reason for cessation attempts (McCaul et al., 2006). Therefore,
there is evidence that expectancies regarding smoking-related health consequences are associated
with motivation to quit smoking. In addition, negative affect reduction expectancies have
significantly predicted abstinence versus relapse among smokers post-cessation. For example,
Copeland et al. (1995) found that negative affect reduction expectancies predicted smoking rates
at 1, 2, 4, and 6 months post-cessation among smokers who had participated in a smoking
cessation intervention. Further, significant pre- to post-treatment decrease in negative affect
reduction expectancies was found among abstainers versus relapsers. In another study using the
SCQ, Wetter et al. (1994) found that higher expectancies for negative reinforcement predicted
smoking at 1-week post-intervention, whereas higher expectancies for negative consequences
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(e.g., health risks) significantly predicted abstinence (Wetter et al., 1994). Smoking expectancies
have been found to change for smokers currently receiving cessation services (Copeland et al.,
1995); however, there is also evidence that expectancies can be directly manipulated. Copeland
and Brandon (2000) showed adult smokers videos related to smoking-related health risks or
smoking-related mood management, followed by an interview to personalize the expectancy
information. Smokers reported lower expectancies for negative affect reduction following the
mood management manipulation, and smokers who viewed the health risks video reported
increased motivation to quit smoking.
Identifying smoking expectancies unique to those with substance use disorders is an area
of research that has received some attention. Hendricks, Peters, Thorne, Delucchi, and Hall
(2014) conducted a study examining smoking expectancies related to adverse outcomes of
quitting smoking among alcohol and drug users. Hendricks et al. (2014) found that adverse
outcome expectancies (e.g., “my drug habit would increase if I quit,” “my use of other drugs
would increase,” “the people close to me would make fun of me for trying to stop smoking,” “I
would feel like a traitor to my fellow smokers,” “I would look less attractive than before,” “I
would not look as cool,” and “I would feel like I had been bullied into quitting”) were associated
with a decreased desire to quit smoking and a decreased likelihood of reporting complete
abstinence as a goal among those who reported using marijuana or opiates. Interestingly,
substance users in this study reported that quitting smoking would not only harm their abstinence
from other substances, but it would also have interpersonal consequences. Smoking expectancies
for positive and negative reinforcement have also been observed within self-help groups, such as
Alcoholics Anonymous. Reich, Dietrich, Finlayson, Fischer, and Martin (2008) found that
smokers attending Alcoholics Anonymous reported negative affect reduction as the most
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important effect of smoking. The findings of Reich et al. (2008) suggest a potential mechanism
by which smoking is perpetuated among smokers who have sought treatment for substance use
disorders. In the early stages of substance use treatment, individuals often find it challenging to
cope with negative affect. Therefore, smoking may be one of the only strategies they have for
managing negative affect. However, as they progress in treatment programs, they learn alternate,
effective coping methods, and as a result, smoking expectancies for negative affect reduction
may decrease. Further research can identify smoking expectancies that are particularly prevalent
among those with substance use disorders and determine if and how their expectancies change as
a function of substance use treatment. Such information can then inform smoking cessation
interventions and tailor them best to meet the needs of this population of smokers.
Rohsenow, Colby, Martin, and Monti (2005) assessed smoking expectancies related to
substance use among individuals admitted to residential substance abuse treatment. Expectancies
regarding the interaction of smoking and substance use were assessed. Examples of these
expectancies are, “Drinking or using drugs results in wanting a cigarette more,” “Smoking gives
me more desire for alcohol or drugs,” “I have smoked a cigarette in order to try to decrease my
urge to drink or use drugs,” and “During treatment for my substance abuse problem, I believe
that I should try to quit smoking.” Positive smoking expectancies were found to be associated
with smoking and increased substance use as well as smoking being used to combat substance
use urges (Rohsenow et al., 2005).
Smoking and Stages of Change
The transtheoretical model provides a framework for understanding stages of behavioral
change and the processes of change that have direct application to several health-related
behaviors. The transtheoretical model integrates several theories of behavior change, including
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Freudian, Skinnerian, and Rogerian, as well as the model of decision-making and self-efficacy
theory. Within the transtheoretical model, six stages of change and ten processes that progress
change have been identified (J. O. Prochaska, Redding, & Evers, 2015). Stages of change include
precontemplation (e.g., no desire to change behavior in the next 6 months), contemplation (e.g.,
considering making changes in the next 6 months), preparation (e.g., intent on taking action
soon), action (e.g., apparent modification in lifestyle has been made), maintenance (e.g., working
to prevent relapse), and termination (e.g., zero temptation for relapse into past behavior).
Processes that progress behavioral change include consciousness raising (e.g., learning new
information to support change), dramatic relief (e.g., increased emotional experiences), selfreevaluation (e.g., assessment of self with and without unhealthy behavior), environmental
reevaluation (e.g., assessment of unhealthy behavior on the environment), self-liberation (e.g.,
belief that change can be made), social liberation (e.g., changes to the environment that support
change), counterconditioning (e.g., developing alternative healthy behaviors), stimulus control
(e.g., removal of cues for unhealthy behavior/ addition of cues to prompt healthy alternatives),
contingency management (e.g., a reward for engagement in health behavior), and helping
relationships (e.g., building social support for behavior change) (J. O. Prochaska et al., 2015).
Stages of change have been widely documented in tobacco literature regarding smoking
behavior and smoking cessation (DiClemente & Prochaska, 1982; DiClemente et al., 1991; J. O.
Prochaska & DiClemente, 1983). Most notably, DiClemente et al. (1991) identified smoking
habits, smoking history, and follow-up cessation rates across stages of change in smokers in a
minimal intervention smoking cessation study. As would be expected, preparation stage smokers
were found to smoke significantly fewer cigarettes, were less nicotine dependent, obtained less
pleasure from smoking, and reported the greatest number of past quit attempts compared to
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precontemplators and contemplators (DiClemente et al., 1991). Furthermore, preparation stage
smokers were found to be most confident in their ability to quit smoking, followed by
contemplators, and then precontemplators. Preparation stage smokers reported the lowest scores
of positive aspects of smoking, followed by contemplators, and then precontemplators. For
reported negative aspects of smoking, precontemplators reported the lowest scores followed by
contemplators, and then preparation stage smokers (DiClemente et al., 1991). Preparation stage
smokers were found to be the most active in behavioral and cognitive processes employed to quit
smoking, with contemplators being more similar to preparation stage smokers on cognitive
processes, but more similar to precontemplators on behavioral processes. At 1-month follow-up,
significantly more of the abstainers were initially identified as preparation stage smokers
compared to contemplators and precontemplators, and at 6-month follow-up, approximately 80%
of preparation stage smokers reported making a 24-hour quit attempt in the past 6 months
(DiClemente et al., 1991). Stages of change are predictive of smoking quit attempts and success
rates in smoking cessation programs. How these stages of change for smoking may evolve for
those with substance use disorders over the duration of time they are in substance use treatment
has not been investigated.
In the context of smokers in substance use treatment it is likely that readiness to quit
smoking and motivation for smoking cessation varies throughout substance use treatment. As a
patient progresses through substance use treatment, he/she is likely to progress through stages of
change for the substance for which treatment was sought. Given that a patient stays in substance
use treatment, he/she may fall in action (e.g., apparent modification in lifestyle has been made)
or maintenance (e.g., working to prevent relapse) stages of change. These stages have been found
to be associated with the self-liberation, counterconditioning, helping relationships,
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reinforcement management, and stimulus control processes of change (J. O. Prochaska et al.,
2015). It is possible that the processes of change resulting from engagement in substance use
treatment may generalize to smoking and progress stage change for smoking behavior. Future
research examining the indirect affect of engagement in substance use treatment on stages of
change for smoking may provide insight into the most appropriate time to provide cessation in
substance use treatment.
The Present Study
Among individuals diagnosed with substance use disorders, smoking rates are
disproportionality high as compared with the general population (Cookson et al., 2014;
USDHHS, 2014; Ward et al., 2012), and tobacco-related mortality is significantly increased
among substance abusers who smoke (Bandiera et al., 2015). Research has identified that
quitting smoking while quitting other substances, is associated with improved long-term
abstinence for primary substances of choice (Kohn et al., 2003; J. J. Prochaska, Delucchi, &
Hall, 2004; Tsoh, Chi, Mertens, & Weisner, 2011). In contrast, there is research supporting that
postponing smoking cessation during substance use treatment is associated with improved longterm abstinence for the substance that treatment was initially sought (Joseph et al., 2004). There
has been a substantial effort in the development of smoking cessation interventions for those in
substance use treatment. Yet, findings have been inconsistent as to if and how these interventions
should overlap in order to optimize success in changing both behaviors. As a result, smoking
cessation has not been consistently made available to smokers in substance use treatment, and
smoking rates among this population remain disproportionately high.
These inconsistencies compelled the current study, in which the primary aim was to
determine how fundamental constructs, such as smoking expectancies and readiness to change,
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vary during substance use treatment. Readiness to change has been well documented as a
predictor of quit attempts and successful cessation among smokers (DiClemente & Prochaska,
1982; DiClemente et al., 1991; J. O. Prochaska & DiClemente, 1983). Health consequence
expectancies have been found to predict motivation to quit and quit attempts (McCaul et al.,
2006; Rose et al., 1996) and negative affect reduction expectancies have been found to predict
continued smoking behavior as well as poor success in cessation programs (Copeland et al.,
1995; Wetter et al., 1994). During substance use treatment, patients are exposed to health-related
behaviors (e.g., dietary and exercise) and psychoeducation about substance use disorders, and
they are also taught new coping skills to deal with stress and negative emotions. It was
anticipated that exposure to health information and the introduction of new coping skills might
generalize to patients’ smoking behavior in substance use treatment. Based on past research on
readiness to change and smoking expectancies, the current study examined when substance user
smokers may be most receptive to engaging in a smoking cessation program during substance
use treatment. The current study consisted of three specific aims,1) identify changes in readiness
to quit smoking over the course of substance use treatment, 2) identify changes in health risk
expectancies over the course of substance use treatment, and 3) identify changes in negative
affect reduction expectancies over the course of substance use treatment. In relation to aim 1, it
was hypothesized that readiness to quit smoking would increase over time spent in substance use
treatment as smokers learn new coping skills and information about the health consequences of
other substances. Learning new coping skills and information about the health consequences of
other substances was hypothesized to generalize to smoking behavior, increasing readiness to
quit. In relation to aim 2, it was hypothesized that health risk expectancies would increase over
time as smokers in substance use treatment learned about the negative health risks related to their
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substance of choice, hypothesized to generalize to health risk smoking expectancies. Lastly, in
relation to aim 3, it was hypothesized that negative affect reduction expectancies would decrease
over time as smokers in substance use treatment learned new coping strategies to manage
negative affect, hypothesized to generalize to negative affect reduction smoking expectancies.
The goal of the current study was to identify how readiness to quit smoking and smoking
expectancies changed over the course of substance use treatment in order to have a more
accurate understanding of when the implementation of a cessation program may be most
beneficial for this population.
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METHODS
Participants
Power Analysis
An a priori repeated measures analysis of variance (ANOVA) power analysis was
conducted using G*Power 3.1 (Faul, Erdfelder, Buchner, & Lang, 2013). Since there were no
existing studies identified in the literature that were similar to the present study and proposed
methodology, an estimated medium effect size was used to determine sample size. It was
determined that a sample size of at least 46 participants was required to detect a medium effect
(partial eta-squared = 0.03) with power of 0.8, and alpha set at 0.05.
Recruitment
Participants were recruited from St. Christopher’s Addiction Wellness Center in Baton
Rouge, LA. St. Christopher’s is a multi-modality based substance use treatment center that
focuses on treating substance use disorders through evidence-based treatments and 12-step
involvement. St. Christopher’s provides and encourages long-term treatment that can last from 6months to 1 year. The first author was checking the electronic medical record (EMR) system
used by St. Christopher’s several times a week to identify newly admitted patients. When a
newly admitted patient was identified, a researcher would go to St. Christopher’s and attempt to
recruit the patient into the study within seven days of a patient’s admittance to treatment. A
researcher in Baton Rouge had several times scheduled throughout the week to meet with newly
admitted patients to reduce the possibility of patients not being recruited within seven days of
admittance to St. Christopher’s. If a patient agreed to participate, the researcher reviewed the
consent and HIPAA agreement form with the potential participant (See Appendix A for Consent
Form; See Appendix B for HIPAA Agreement Form).
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Criteria for eligibility. In order for participants to be eligible they had to be 1) admitted
at St. Christopher’s during the dates of data collection; 2) ≥ 18 years of age at the initial study
visit; 3) a current smoker (i.e., at least weekly smoking and an expired carbon monoxide monitor
reading of 8 > parts per million); 4) not mandated by court system to attend substance use
treatment; and 5) able to demonstrate a 7th grade reading level or higher.
Criteria for exclusion. Individuals were excluded from the study if they were: 1)
discharged from St. Christopher’s; 2) < 18 years of age; 3) not current smokers as determined
above; 4) mandated by court system to attend substance use treatment; or 5) unable to
demonstrate a 7th grade reading level or higher.
Measures and Materials
All participants completed an assessment of literacy at baseline. All participants
completed the demographic and smoking questionnaire, breath analysis for carbon monoxide,
and assessments of readiness to change, smoking expectancies, and nicotine dependence at
baseline, 30-day, 60-day, and 90-day follow-ups. The first author would access St. Christopher’s
charts to retrieve substance use and mental health history information for participants.
Literacy
The Rapid Estimate of Adult Literacy in Medicine—Short Form (REALM - SF;
Arozullah et al., 2007). The REALM – SF is a 7-item word recognition test that provides a valid
quick assessment of patient health literacy. Additionally, the REALM – SF can be used to
evaluate grade level reading ability (e.g., 3rd grade and below, fourth to sixth grade, seventh to
eight grade, and high school). (See Appendix C for the REALM – SF).
Questionnaire
The demographic questionnaire is a brief self-report questionnaire that was used to gather
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demographic information as well as basic information on current and past smoking behavior.
(See Appendix D for the Demographic Questionnaire).
Substance Use and Mental Health Form
Newly admitted patients to St. Christopher’s would meet with a psychiatrist or
psychiatric nurse practitioner for a psychiatric evaluation and psychosocial assessment in which
diagnoses were made per the Diagnostic and Statistical Manual-5th Edition (DSM-5). Other
psychosocial assessment information (e.g., number of substance use treatment programs
attended, last use of any substance, age of first substance use, and longest period of abstinence
from substances) was retrieved from the intake completed by staff (e.g., counselor or tech) upon
a patient’s admittance to St. Christopher’s. (See Appendix E for Substance Use and Mental
Health Form).
Readiness to Change
University of Rhode Island Stages of Change Assessment (URICA; McConnaughy,
Prochaska, & Velicer, 1983). The URICA is a 32-item self-report questionnaire that measures
readiness for behavioral change. Four subscales, including precontemplation, contemplation,
preparation (action), and maintenance are used to compute a total readiness score. The URICA
has been found to have good reliability with coefficient alpha’s ranging from 0.88 to 0.89 across
subscales. Of these 32-items, more recent research on the URICA has suggested the omission of
4-items (1 from each subscale) for a total of 28-items used in the calculation of the total
readiness score (Carbonari & DiClemente, 2000; DiClemente & Hughes, 1990). Items are rated
on a 5-point scale ranging from 1, “strongly disagree,” to 5, “strongly agree.” To calculate the
readiness to change score, the mean scores for all subscales are calculated. The mean score from
the precontemplation subscale is subtracted from the sum of mean scores of the contemplation,
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preparation (action), and maintenance subscales to calculate readiness to change. Higher total
scores are associated with increased readiness to change. The readiness to change score can be
transformed from a continuous variable to a categorical variable to identify progression through
stages of change. The URICA is a widely used, reliable and valid measure to assess motivation
for behavior change in smokers and those with substance use disorders (Norcross, Krebs, &
Prochaska, 2011). (See Appendix F for the URICA).
Smoking Expectancies
Smoking Consequences Questionnaire – Adult (SCQ - A; Copeland et al., 1995). The
SCQ-A is a 55-item self-report measure that assesses several smoking expectancies among adult
smokers. There are ten domains of smoking expectancies, including negative affect reduction,
stimulation/state enhancement, health risks, taste/sensorimotor manipulation, social facilitation,
appetite/ weight control, craving/addiction, negative physical feelings, boredom reduction, and
social impression. For the current study, only the negative affect reduction and health risks
subscales were included in the main analyses. Items are rated on a 10-point scale ranging from 0,
“completely unlikely,” to 9, “completely likely” for each domain, with higher scores reflecting
the increased likelihood of believing an expectancy to occur after smoking. The SCQ-A has been
found to have great reliability with coefficient alpha’s ranging from 0.97 to 0.78 across domains.
(See Appendix G for the SCQ – A).
Smoking
Carbon Monoxide Monitor Reading (Benowitz et al., 2002). A carbon monoxide
monitor is a non-intrusive and well established biochemical measure of assessing current
smoking status. A participant blows through a tube, which measures parts per million (ppm) of
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carbon monoxide in expired breath. A cut-off of 8 ppm or above has been established as an
appropriate cut-off for identifying current smokers.
The Fagerström Test for Nicotine Dependence (FTND; Heatherton, Kozlowski,
Frecker, & Fagerstrom, 1991). The FTND is a 6-item self-report measure that assesses nicotine
dependence. Different items have different response options (e.g., yes/no vs. categorical
responses). Each response option is associated with a number of points used to calculate a single
score. Higher scores are associated with increased nicotine dependence. The FTND has been
found to have poor internal consistency with a reported coefficient alpha of 0.61. However,
research has attributed this poor internal consistency to the low number of items within this
measure. It is widely used within research looking at smoking. (See Appendix H for the FTND).
Study Procedure
Initial Visit
At the initial meeting, the researcher and participant would first review the consent
forms, study requirements, and potential risks of participation. If a patient was eligible and
expressed interest in participating, he was assigned a participant ID and then was administered
the REALM – SF to assess for literacy. If a participant was able to demonstrate a 7th grade
reading level or higher he then completed the baseline assessment, including a demographic and
smoking questionnaire, breath analysis for carbon monoxide level, the URICA, the SCQ – A,
and the FTND. Participants were then informed that a researcher would come to St.
Christopher’s to conduct the follow-up appointment 30 days from the prior assessment.
Participants could be met within 4 days before or after their follow-up assessment date in order
to provide flexibility in scheduling. After baseline assessments were completed, the first author
obtained additional information from the patient’s chart, including documentation on substance
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use and mental health history. This information was transferred onto a hard copy form. Only the
first author had access to patient charts. The first author completed all Substance Use and Mental
Health Forms. The Substance Use and Mental Health Forms were stored with other baseline
assessment measures in a confidential and secure location.
Thirty- and Sixty-day Assessment
At the 30- and 60-day follow-up, participants completed all baseline assessments
including the demographic and smoking questionnaire, breath analysis for carbon monoxide, and
the URICA, SCQ – A, and FTND. Upon completion of each follow-up assessment, a researcher
would come to St. Christopher’s to conduct the next follow-up appointment 30 days from the
prior assessment. Participants could be met within 4 days before or after their follow-up
assessment date in order to provide flexibility in scheduling.
Ninety-day Assessment
At the 90-day follow-up, participants followed study protocols outlined in the 30- and 60day follow-up visits. After the participant completed the study measures, he was informed to
contact the researcher with any questions.
Revision to Follow-up Assessment Procedure. As data collection proceeded, the
completion of follow-up assessments became increasingly difficult due to several program
changes at St. Christopher’s. First, the head admissions counselor resigned from St.
Christopher’s. This resulted in shorter treatment stays, as the admissions counselor had actively
recruited patients to commit to long-term treatment. Several staff who had initially agreed to
assist with data collection were no longer working at St. Christopher’s or were working in other
positions within the facility. In response to these unexpected difficulties, the protocol for
collecting follow-up assessments was revised. The research team consulted directly with
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treatment staff as to how to improve completion of follow-up assessments, and staff suggested
that the researchers contact on-site staff or counselors prior to follow-up assessments to obtain
updates on participant phase transition or discharge. Researchers would contact staff or
counselors several days in advance of follow-up assessments in an attempt to locate participants
prior to transitions or discharges.
Confidentiality of Materials
Once a participant completed self-report measures, a researcher brought those materials
to Louisiana State University (LSU) where they were kept in the Smoking and Substance Use
Research Laboratory in a locked filing cabinet.
Institutional Review Board
The current study was reviewed and approved by the LSU Institutional Review Board
and the Institutional Review Board at St. Christopher’s Addiction Wellness Center. A Certificate
of Confidentiality from the National Institute of Drug Abuse was requested and approved to
protect participant information. A Certificate of Confidentiality provides additional protection to
participants by allowing the researchers the right “to refuse to disclose identifying information
on research participants in any civil, criminal, administrative, legislative, or other proceeding,
whether at the federal, state, or local level.” (National Institute on Drug Abuse, 2015). The
Certificate of Confidentiality was one additional step taken to ensure data collected was not used
in a way that could potentially put participants at risk.
Study Design
Readiness to change has been established as a predictor of quit attempts and successful
cessation among smokers (DiClemente & Prochaska, 1982; DiClemente et al., 1991; J. O.
Prochaska & DiClemente, 1983). Furthermore, health risk smoking expectancies and negative
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affect reduction smoking expectancies have been identified as predictors of motivation to quit
and quit attempts (McCaul et al., 2006; Rose et al., 1996) and have been found to predict
continued smoking behavior as well as poor success in cessation program (Copeland et al., 1995;
Wetter et al., 1994). However, to our knowledge, no studies have tracked how readiness to quit
smoking and these specific smoking expectancies change for smokers in long-term substance use
treatment. During substance use treatment, smokers learn about health consequences related to
their primary substance use disorder and effective coping strategies to manage negative affect. It
was hypothesized that information learned in substance use treatment would generalize to
smoking behavior, change readiness to quit smoking, and health risk and negative affect
reduction expectancies over time.
The current study consists of three specific aims. The first aim was to identify if readiness
to quit smoking changed over the course of substance use treatment. The second aim was to
identify if health risk expectancies changed over the course of substance use treatment. Lastly,
the third aim was to identify if negative affect reduction expectancies changed over the course of
substance use treatment. For these aims changes in readiness to quit smoking, health risk
expectancies, and negative affect reduction expectancies were analyzed separately as they have
been found to be distinct constructs within the literature in regard to predicting different
smoking-related behaviors (e.g., intention to quit, continued smoking, and success in cessation).
Aim 1
For aim 1, a longitudinal design was used to identify if readiness to quit smoking changed
over the course of 90 days in substance use treatment at four predetermined time points.
Hypothesis 1. For aim 1, it was hypothesized that readiness to quit smoking would
increase over time as a result of smokers in substance use treatment learning new coping skills
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and information about the negative health risks of their substance of choice. The acquisition of
skills and information were hypothesized to generalize to smoking behavior, making smokers
more receptive to quitting smoking and in turn increasing readiness to quit smoking.
Aim 2
For aim 2, a longitudinal design was used to identify if health risk expectancies changed
over the course of 90 days in substance use treatment at four predetermined time points.
Hypothesis 2. For aim 2, it was hypothesized that health risk smoking expectancies
would increase over time as a result of smokers in substance use treatment learning healthoriented information and information about the negative health effects of other substances. The
information learned in treatment about the negative health effects of other substances was
hypothesized to generalize to health risk smoking expectancies.
Aim 3
For aim 3, a longitudinal design was used to identify if negative affect reduction
expectancies changed over the course of 90 days in substance use treatment at four
predetermined time points.
Hypothesis 3. For aim 3, it was hypothesized that negative affect reduction smoking
expectancies would decrease over time as a result of smokers in substance use treatment learning
other coping skills to manage negative affect other than smoking. Coping skills learned to
manage negative affect were expected to generalize to negative affect reduction smoking
expectancies.
Statistical Procedure
Before conducting the statistical analyses to test the 3 hypotheses, analyses were
conducted to identify participants who completed assessments past baseline and which
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participants had missing data on self-report measures across assessments. Participants identified
as having completed baseline and one or more follow-up assessments were included in final
analyses. Comparison analyses were conducted on baseline variables and measures to identify
significant differences between participants who complete the baseline assessment only and
participants who completed the baseline assessment and one or more follow-up assessments.
Mean substitution, a conservative approach, was used to account for missing data on the URICA
and SCQ-A for aims 1, 2, and 3. Statistical Package for the Social Sciences (SPSS) version 24
was employed to determine the reliability of measures included, such as the URICA, SCQ-A,
and FTND. A correlation table was generated to determine if any of the demographic variables
(age, education, employment, ethnicity), as well as information taken from the Substance Use
and Mental Health Form including diagnostic variables (substance use disorders and
psychological disorders), number of substance use treatment programs attended, last use of any
substance, age of first substance use, and longest period of abstinence from substances were
correlated with measures used in aims 1, 2, and 3. Baseline variables that correlated with the
URICA, SCQ-A Health Risks subscale, and SCQ-A Negative Affect Reduction subscale were
not included in the analyses for aims 1, 2, and 3 due to the small sample size. A second
correlation table was generated to identify correlations between the variables described above in
the overall sample.
SPSS version 24 was employed to conduct repeated measures ANOVAs for aims 1, 2,
and 3. Readiness to change, health risk smoking expectancies, and negative affect reduction
smoking expectancies were the three continuous variables assessed across time. Bonferonni
correction, the most conservative correction that can be performed, was applied to all repeated
measures ANOVAs to control for the increased probability of a Type 1 error occurring.
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RESULTS
Participant Recruitment and Follow-up
Of the 132 patients who were admitted to St. Christopher’s between March 26 th, 2019
and December 12th, 2019, 102 patients were contacted to participate in the current study. Of the
30 patients who were not contacted, 19 were not reached within seven days from being admitted
to St. Christopher’s due to researcher availability, 2 were unavailable due to being ill/
hospitalized, and 9 decided against entering treatment at St. Christopher’s. Out of the 102
patients, 52 were eligible and interested in participating, and 50 were excluded. Reasons for
exclusion included being court-ordered for treatment (n = 4), having a CO reading being below 8
ppm (n = 2), identifying as a nonsmoker (n = 19), being under 18 years of age (n = 3), and not
being interested due to a number of reasons (e.g., lack of incentives and persuasion from other
patients to not participate) (n = 22). During the baseline assessment, one participant was
excluded due to psychosis, which became apparent after he consented to participate. A total of
51 participants completed the baseline assessment, 13 completed the 30-day follow-up, 9
completed the 60-day follow-up, and 3 completed the 90-day follow-up. Some participants who
completed the 30-day follow-up were not available for the 60-day follow-up, and some of the
participants who did not complete the 30-day follow-up were later available for the 60-day
follow-up. Sixteen participants completed the baseline assessment and one or more of the followups, including the 30-day or 60-day follow-up, or both. These 16 participants were included in
the analyses to test the 3 hypotheses. Mean substitution was not implemented for the 90-day
follow-up assessment as so few participants completed this follow-up assessment. See Figure 1
for participant retention.
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Patient Admits to St. Christopher’s Addiction
Wellness Program
3/26/19 – 12/12/19
(N = 132 )

Patients Not Approached (n = 30)
-Not reached within 7 day time frame for baseline assessment (n = 19)
-Ill/ Hospitalized (n = 2)
-Patient decided not to admit to St. Christopher’s (n = 9)

Patients Approached and Screened
for Eligibility
(n = 102)

Excluded (n = 51)
-Inclusion criteria not met (n = 28)
-Not Interested (n = 22)
-Withdrew (n = 1)

Included (n = 51)

Completed Baseline Assessment (n = 51)

Eligible for 30-day Follow-up (n = 51)

Eligible for 60-day Follow-up ( (n = 28)
-30-day completers (n = 13)
-30-day unable to complete (n = 8)
-30-day Ill/ Hospitalized (n = 7)

Eligible for 90-day follow-up (n = 18)
-60-day completers (n = 9)
-60-day unable to complete (n = 8)
-60-day Ill/ Hospitalized (n = 1)

Completed 30-day Follow-up (n = 13)
Completed 60-day Follow-up (n = 9)

Excluded (n = 38)
-Left treatment (n = 22)
-Unable to complete during time frame window due
to researcher or participant availability (n = 8)
-Ill/ Hospitalized (n = 7)
-Withdrew (n = 1)

Excluded (n = 19)
-Left treatment (n = 8)
-Unable to complete during time frame window due to
researcher or participant availability (n = 8)
-Ill/ Hospitalized (n = 1)
-Withdrew (n = 2)

Figure 1. Participant Retention through Study Phases
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Completed 90-day Follow-up (n = 3)

Excluded (n = 15)
-Left treatment (n = 5)
-Unable to complete during time frame window due to
researcher or participant availability (n = 7)
-Graduated treatment (n = 3)

Participant Characteristics
Characteristics of Overall Sample
Participants (N = 51) were adults currently enrolled in substance use treatment at St.
Christopher’s Addiction Wellness Center in Baton Rouge, LA. The overall sample was male
(100%) and the majority was White (96.1%). Mean age was 31.1 (SD = 11.0) years. On average,
participants reported smoking for 12.9 years (SD = 11.0), and most were daily smokers (90.2%).
See Table 1 for baseline characteristics for the overall sample, participants who completed the
baseline assessment only, and participants who completed the baseline assessment and one or
more follow-ups.
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Table 1. Participant Characteristics
Past Baseline
Baseline

Completers

All Participants

(n = 35),

(n = 16),

(N = 51),

M (SD) or %

M (SD) or %

M (SD) or %

Last use of any substance (days)

10.1 (9.6)

8.7 (10.4)

9.6 (9.8)

Age of first substance use

13.2 (3.5)

11.9 (2.0)

12.7 (3.1)

Number of treatment centers attended

1.4 (1.6)

1.9 (2.1)

1.6 (1.8)

539.3 (831.9)

341.7 (527.6)

466.5 (733.0)

CO monitor reading (ppm)

27.6 (15.2)

29.5 (13.6)

28.2 (14.6)

Age

32.2 (10.4)

28.6 (12.4)

31.1 (11.0)

Education (years)

13.3 (2.1)

13.7 (2.4)

13.4 (2.2)

50,964.4 (39,310.4)

33,933.3 (38,246.4)

45,528.9 (39,382.7)

Employment status (% unemployed)

42.9%

62.5%

49%

Ethnicity (% white)

94.3%

100%

96.1%

Cigarettes smoked per day

16.2 (8.5)

14.9 (7.2)

15.8 (8.1)

How many serious quit attempts prior to STC

2.1 (3.2)

1.4 (1.8)

1.9 (2.9)

Number of substance use disorders*

1.6 (1.0)

2.2 (0.8)

1.8 (1.0)

Number of other psychological disorders

1.0 (0.8)

1.4 (0.8)

1.1 (0.8)

FTND

4.9 (2.0)

4.1 (2.8)

4.7 (2.3)

URICA

8.7 (3.4)

8.8 (3.9)

8.7 (3.5)

SCQ-A Health Risks

7.2 (2.6)

8.2 (1.1)

7.5 (2.3)

SCQ-A Negative Affect Reduction

6.2 (2.7)

5.2 (2.0)

5.9 (2.5)

Characteristics

Longest period of abstinence

Annual household income

Note: M = Mean, SD = Standard Deviation
* Denotes significance (p < 0.05) on demographic variables between participants who completed baseline
assessments and those who completed baseline and one or more follow-ups.
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Characteristics of Participants Included in Analyses for Aims 1, 2, and 3
Participants (N = 16) included in aims 1, 2, and 3 were all male (100%) and White
(100%), and the mean age was 28.6 (SD = 12.4) years. On average, participants reported
smoking for 12.7 years (SD = 13.3), and the majority of the sample identified as daily smokers
(93.8%).
Reliability of Measures
The URICA consisted of 32-items (28 were used in analyses) and had good internal
reliability (α = 0.87). The two domains taken from the SCQ-A displayed good to excellent
internal reliability. The SCQ-A Negative Affect Reduction domain consisted of 9-items and
displayed excellent internal reliability (α = 0.95). The SCQ-A Health Risks domain consisted of
4-items and displayed good internal reliability (α = 0.88). The FTND consisted of 6-items and
displayed poor internal reliability (α = 0.58). Past research has found the FTND to have
questionable internal reliability, which was anticipated in the current study. The URICA was
used as the outcome measure in aim 1, the SCQ-A Health Risks domain was used as the outcome
measure in aim 2, and the SCQ-A Negative Affect Reduction domain was used as the outcome
measure in aim 3.
Baseline Measures
Overall Sample Baseline Measures
On the URICA, the mean readiness to change score was 8.7 (SD = 3.5). The URICA was
transformed to a categorical variable to identify the prevalence of specific stages. Analyses
indicated that in the overall sample, 35.4% of participants were in the precontemplation stage,
33.3% of participants were in the contemplation stage, 29.2% were in the preparation (action)
stage, and 2.1% were in the maintenance stage. On the SCQ-A Health Risks subscale the mean
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score was 7.5 (SD = 2.3) and on the SCQ-A Negative Affect Reduction subscale the mean score
was 5.9 (SD = 2.5).
Participant Comparisons on Baseline Measures
Analyses were run to identify differences on baseline characteristics and measures
between participants who completed the baseline assessment only (n = 35) and those who
completed the baseline assessment and one or more follow-ups (n = 16).
Comparisons on Baseline Characteristics. The only significant difference on baseline
characteristics was the number of substance use disorders present, reported by the psychiatrist or
nurse practitioner, between those who completed the baseline assessment only (M = 1.6, SD =
1.0) and those who completed the baseline assessment and one or more follow-ups (M = 2.2, SD
= 0.8), t (41) = -2.02, p = 0.050. Participants who completed the baseline assessment and one or
more follow-up assessments tended to have more substance use disorders.
URICA. On the URICA, there was no significant difference between participants who
completed the baseline assessment only (M = 8.7, SD = 3.4) and participants who completed the
baseline assessment and one or more follow-ups (M = 8.8, SD = 3.9), t (46) = -0.09, p = 0.926.
The baseline assessment URICA readiness to change score was transformed to a categorical
variable to examine prevalence of reported stage of change between participants who completed
the baseline assessment only and participants who completed the baseline and one or more
follow-ups. Analyses indicated among participants who completed the baseline assessment only,
42.4% were in the precontemplation stage, 30.3% were in the contemplation stage, 24.2% were
in the preparation (action) stage, and 3% were in the maintenance stage. Among participants who
completed baseline and one or more follow-ups 20% were in the precontemplation stage, 40%
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were in the contemplation stage, 40% were in the preparation (action) stage, and none were in
the maintenance stage.
SCQ-A Health Risks. On the SCQ-A Health Risks subscale, there was no significant
difference between participants who completed the baseline assessment only (M = 7.2, SD = 2.6)
and participants who completed the baseline assessment and one or more follow-ups (M = 8.2,
SD = 1.1), t (46.87) = -1.91, p = 0.062.
SCQ-A Negative Affect Reduction. On the SCQ-A Negative Affect Reduction subscale,
there was no significant difference between the participants who completed the baseline
assessment only (M = 6.2, SD = 2.7) and participants who completed the baseline assessment
and one or more follow-ups (M = 5.2, SD = 2.0), t (47) = 1.20, p = 0.238.
Correlations
Baseline Correlations of Overall Sample
Education was negatively correlated with longest period of abstinence from substances (r
= -0.33, p = 0.049) and positively correlated with age (r = 0.31, p = 0.037). Years smoking was
positively correlated with age (r = 0.81, p = 0.000). Cigarettes smoked per day was positively
correlated with CO reading (r = 0.61, p = 0.000), age (r = 0.31, p = 0.034), and years smoking (r
= 0.46, p = 0.001). Number of substance use disorders present was positively correlated with age
of first substance use (r = 0.34, p = 0.026) and negatively correlated with age (r = -0.34, p =
0.024). The FTND was positively correlated with CO reading (r = 0.33, p = 0.022), age (r =
0.35, p = 0.015), years smoking (r = 0.42, p = 0.003), and cigarettes smoked per day (r = 0.55, p
= 0.000). The SCQ-A Health Risks subscale was positively correlated with number of substance
use treatment centers attended (r = 0.37, p = 0.013), years smoking (r = 0.35, p = 0.016), and the
URICA (r = 0.41, p = 0.005). The SCQ-A Negative Affect Reduction subscale was negatively
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correlated with days since last use of any substances (r = -0.47, p = 0.002) and positively
correlated with the FTND (r = 0.39, p = 0.006), the URICA (r = 0.36, p = 0.015), and the SCQ-A
Health Risks subscale (r = 0.39, p = 0.007). See Table 2 for correlations of the overall sample.
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Table 2. Correlations among baseline study variables for overall sample (N = 51)
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2. Age of first use

-0.12

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3. # Treatment centers

-0.09

-0.09

-

-

-

-

-

-

-

-

-

-

-

-

-

4. Longest abstinence

-0.15

0.04

0.06

-

-

-

-

-

-

-

-

-

-

-

-

5. CO (ppm) a

-0.29

-0.20

0.00

-0.07

-

-

-

-

-

-

-

-

-

-

-

6. Age

0.20

0.03

0.01

0.20

-0.04

-

-

-

-

-

-

-

-

-

-

7. Education

0.29

-0.15

0.27

-0.33*

-0.18

0.31*

-

-

-

-

-

-

-

-

-

8. Years smoking

0.17

-0.17

-0.07

0.16

0.09

0.81***

0.21

-

-

-

-

-

-

-

-

9. CPD b

-0.16

-0.23

-0.20

0.05

0.61***

0.31*

-0.02

0.46**

-

-

-

-

-

-

-

10. Quit attempts prior

-0.12

0.00

0.18

0.33

0.08

-0.04

0.04

-0.07

0.10

-

-

-

-

-

-

11. SUD c

-0.16

0.34*

-0.03

-0.16

-0.15

-0.34*

0.02

-0.27

-0.26

-0.19

-

-

-

-

-

12. Psychological disorders

-0.18

-0.01

-0.14

0.01

0.02

-0.15

-0.11

-0.10

-0.03

-0.03

0.27

-

-

-

-

13. FTND

-0.21

-0.04

-0.05

0.14

0.33*

0.35*

-0.18

0.42**

0.55***

0.11

-0.25

-0.16

-

-

-

14. URICA

-0.11

0.09

0.20

0.13

0.20

-0.04

-0.24

0.03

0.03

-0.01

0.01

-0.19

0.14

-

-

15. SCQ-A Health Risks

-0.05

-0.09

0.37*

0.15

0.27

0.26

0.14

0.35*

0.07

0.17

0.08

0.05

0.21

0.41**

-

-0.47**

0.01

0.16

0.14

0.22

0.09

-0.21

0.08

0.12

0.10

0.01

-0.07

0.39**

0.36*

0.39**

1. Last use of substance

16. SCQ-A Negative Affect
a

CO (ppm) = Carbon monoxide (parts per million)

b

CPD = Cigarettes per day

c

SUD = Substance use disorders

*p < 0.05; **p < 0.01, ***p < 0.001
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Baseline Correlations of Participants Included in Analyses for Aims 1, 2, and 3
Education was negatively correlated with CO reading (r = -0.50, p = 0.050.) Years
smoking was positively correlated with age (r = 0.94, p = 0.000). Cigarettes smoked per day was
positively correlated with CO reading (r = 0.52, p = 0.047), age (r = 0.62, p = 0.013), and years
smoking (r = 0.69, p = 0.004). Number of smoking quit attempts prior to entering St.
Christopher’s was positively correlated with longest period of abstinence from substances (r =
0.58, p = 0.048). Number of psychological disorders was negatively correlated with age (r = 0.59, p = 0.026) and education (r = -0.67, p = 0.008). The FTND was positively correlated with
CO reading (r = 0.65, p = 0.009), years smoking (r = 0.62, p = 0.013), and cigarettes smoked per
day (r = 0.86, p = 0.000). The SCQ-A Health Risks subscale was positively correlated with the
URICA (r = 0.56, p = 0.026). The SCQ-A Negative Affect Reduction subscale was negatively
correlated with days since last use of any substances (r = -0.58, p = 0.023) and positively
correlated with CO reading (r = 0.67, p = 0.005), cigarettes smoked per day (r = 0.59, p = 0.021),
and the FTND (r = 0.57, p = 0.026). See Table 3 for correlations of the participants included in
analyses for aims 1, 2, and 3.
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Table 3. Correlations among baseline study variables for main analyses sample (n = 16)
1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2. Age of first use

-0.05

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3. # Treatment centers

0.09

0.12

-

-

-

-

-

-

-

-

-

-

-

-

-

4. Longest abstinence

-0.05

0.14

0.28

-

-

-

-

-

-

-

-

-

-

-

-

5. CO reading a

-0.44

-0.21

-0.03

0.05

-

-

-

-

-

-

-

-

-

-

-

6. Age

-0.07

0.29

-0.14

0.31

-0.04

-

-

-

-

-

-

-

-

-

-

7. Education

0.29

0.27

0.31

0.39

-0.50*

0.42

-

-

-

-

-

-

-

-

-

8. Years smoking

-0.04

0.16

-0.11

0.44

0.15

0.94***

0.25

-

-

-

-

-

-

-

-

9. CPD b

-0.35

0.00

-0.07

-0.08

0.52*

0.62*

0.01

0.69**

-

-

-

-

-

-

-

10. Quit attempts prior

-0.30

0.03

0.01

0.58*

0.47

-0.04

-0.08

0.04

0.05

-

-

-

-

-

-

11. SUD c

0.05

0.03

0.15

-0.02

-0.27

-0.42

0.02

-0.39

-0.23

-0.19

-

-

-

-

-

12. Psychological disorders

-0.11

-0.17

-0.17

-0.45

0.10

-0.59*

-0.67**

-0.42

-0.25

-0.24

0.47

-

-

-

-

13. FTND

-0.41

-0.32

0.02

-0.12

0.65**

0.50

-0.09

0.62*

0.86***

0.25

-0.45

-0.26

-

-

-

14. URICA

0.20

-0.09

0.04

0.19

0.28

0.09

-0.10

0.13

0.06

-0.09

-0.22

-0.13

0.03

-

-

15. SCQ-A Health Risks

0.25

0.32

0.17

0.31

0.21

0.20

0.19

0.15

0.13

0.23

-0.04

-0.51

0.12

0.56*

-

-0.58*

0.00

-0.03

0.05

0.67**

0.16

-0.08

0.17

0.59*

0.46

0.10

-0.16

0.57*

0.08

0.21

1. Last use of substance

16. SCQ-A Negative Affect
a

CO (ppm) = Carbon monoxide (parts per million)

b

CPD = Cigarettes per day

c

SUD = Substance use disorders

*p < 0.05; **p < 0.01, ***p < 0.001
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Missing Data
If a participant was unable to be reached within the time frame window for a follow-up
assessment, due to participant or researcher availability, a researcher attempted to contact him at
the next time point. As a result, there were several participants who completed the 60-day
follow-up who were missing data from the 30-day visit and several participants who completed
the 30-day follow-up who were missing data from the 60-day follow-up. Of these participants
who completed one or more follow-ups, 13 completed the 30-day follow-up, 9 completed the 60day follow-up, and 3 completed the 90-day follow-up. 16 participants were identified as
completing the baseline assessment and one or more follow-up assessments. Of these 16
participants, there was one who did not respond to items on the baseline URICA and one who
did not respond to items on the baseline SCQ-A Health Risks subscale. However, both of these
participants completed all of the 30- and 60-day follow-up measures and were included in the
main outcome analyses. Missing value analyses were conducted to identify the percentage of
missing data across time points for scores on the URICA, SCQ-A Health Risks subscale, and the
SCQ-A Negative Affect Reduction subscale. On the URICA, 6.3% (n = 1) of data was missing at
baseline, 18.8% (n = 3) of data was missing at 30-day follow-up, and 43.8% (n = 7) of data was
missing at the 60-day follow-up. On the SCQ-A Health Risks subscale, 6.3% (n = 1) of data was
missing at baseline, 18.8% (n = 3) of data was missing at 30-day follow-up, and 43.8% (n = 7) of
data was missing at the 60-day follow-up. On the SCQ-A Negative Affect Reduction subscale,
0% (n = 0) of data was missing at baseline, 18.8% (n = 3) of data was missing at 30-day followup, and 43.8% (n = 7) of data was missing at the 60-day follow-up. At baseline and 30- and 60day follow-up, mean substitution was implemented for scores on outcome variables. For tests of
the 3 main hypotheses, data from the 90-day follow-up were excluded, as mean substitution was
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not appropriate for such a small sample size. Mean substitution was implemented to handle
missing data only on outcome variables (e.g., URICA, SCQ-A Health Risks subscale, and SCQA Negative Affect Reduction subscale). While mean substitution does have limitations, it is a
conservative procedure for handling missing data (Tabachnick & Fidell, 2013). Mean
substitution was implemented to reduce the risk of a Type I error occurring. For the URICA,
mean substitution was calculated for the Readiness to Change score, a continuous variable. For
the SCQ-A mean substitution was used for the final scores on each subscale (e.g., the mean of
each subscale). See Table 4 for scores on outcome variables with mean substitution
implemented.
Table 4. Scores on outcome variables with mean substitution implemented (n = 16)
Baseline

30-day follow-up

60-day follow-up

M (SD)

M (SD)

M (SD)

URICA

8.8 (3.8)

9.0 (2.6)

8.6 (2.2)

SCQ-A Health Risks

8.2 (1.0)

8.1 (1.4)

6.4 (2.2)

SCQ-A Negative Affect

5.2 (2.0)

5.5 (1.8)

3.8 (1.9)

Note: M = Mean, SD = Standard Deviation

Aim 1
Repeated Measures ANOVA
A repeated measures ANOVA was conducted to determine differences on URICA scores
across assessments. Bonferonni correction was applied to post hoc analyses to control for the
increased probability of a Type 1 error occurring.
Mauchly’s Test of Sphericity revealed the assumption of sphericity had not been violated,
χ2 (2) = 5.56, p = 0.062. A repeated measures ANOVA revealed that URICA scores did not
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differ significantly between time points F (2, 30) = 0.09, p = 0.912. See Table 4 for scores on the
URICA across time points.
Aim 2
Repeated Measures ANOVA
A repeated measures ANOVA was conducted to determine differences in SCQ-A Health
Risks subscale scores across assessments. Bonferonni correction was applied to post hoc
analyses to control for the increased probability of a Type 1 error occurring.
Mauchly’s Test of Sphericity revealed the assumption of sphericity had not been violated,
χ2 (2) = 4.55, p = 0.103. A repeated measures ANOVA revealed that SCQ-A Health Risks
subscale scores differed significantly between time points F (2, 30) = 5.68, p = 0.008, ηp2 = 0.28.
Post hoc tests using Bonferroni correction detected no significant difference between baseline (M
= 8.2, SD = 1.0) and 30-day follow-up (M = 8.1, SD = 1.4) (p = 1.000). There were no significant
differences between baseline (M = 8.2, SD = 1.0) and 60-day follow-up (M = 6.4, SD = 2.2) (p =
0.068). However, there was a significant difference between 30-day follow-up (M = 8.1, SD =
1.4) and 60-day follow-up (M = 6.4, SD = 2.2) (p = 0.050). See Table 4 for scores on the SCQ-A
Health Risks subscale across time points.
Aim 3
Repeated Measures ANOVA
A repeated measures ANOVA was conducted to determine differences in SCQ-A
Negative Affect Reduction subscale scores across assessments. Bonferonni correction was
applied to post hoc analyses to control for the increased probability of a Type 1 error occurring.
Mauchly’s Test of Sphericity revealed the assumption of sphericity had not been violated,
χ2 (2) = 1.61, p = 0.446. A repeated measures ANOVA revealed that SCQ-A Negative Affect
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Reduction subscale scores differed significantly between time points F (2, 30) = 6.70, p = 0.004,
ηp2 = 0.31. Post hoc tests using Bonferroni correction detected no significant difference between
baseline (M = 5.2, SD = 2.0) and 30-day follow-up (M = 5.5, SD = 1.8) (p = 1.000). There was a
significant differences between baseline (M = 5.2, SD = 2.0) and 60-day follow-up (M = 3.8, SD
= 1.9) (p = 0.018) and a significant difference between 30-day follow-up (M = 5.5, SD = 1.8) and
60-day follow-up (M = 3.8, SD = 1.9) (p = 0.030). See Table 4 for scores on the SCQ-A
Negative Affect Reduction subscale across time points.
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DISCUSSION
The purpose of the current study was to determine whether readiness to change, health
risk smoking expectancies and negative affect reduction smoking expectancies differed between
baseline assessment, 30-day follow-up, and 60-day follow-up for smokers in substance use
treatment. In relation to aim 1, it was hypothesized that readiness to quit smoking would increase
over time as smokers in substance use treatment learned new coping skills and information about
the negative health risks of other substances. It was hypothesized that this information would
generalize to smoking behavior, and thereby increase readiness to quit smoking. In relation to
aim 2, it was hypothesized that health risk smoking expectancies would increase over time as
smokers in substance use treatment learned health-oriented information and information about
the negative health effects of substance abuse. The information learned in treatment about the
negative health effects of other substances was hypothesized to generalize to smoking. In relation
to aim 3, it was hypothesized that negative affect reduction smoking expectancies would
decrease over time due to smokers in substance use treatment learning other coping skills to
manage negative affect other than smoking. Analyses indicated changes in readiness to quit
smoking were not significantly different across assessments. This finding was contrary to the
hypothesis that readiness to quit smoking would increase with time spent in substance use
treatment. There was a significant change over time in expectancies for health risks, but it was in
the opposite direction of that hypothesized. That is, health risk expectancies significantly
decreased over time in treatment. Lastly, there was a significant change over time in negative
affect reduction expectancies occurring in the hypothesized direction with decreased scores
identified at the 60-day assessment.
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Baseline Characteristics and Measures
Overall Sample
In the overall sample, a majority of participants were identified as being in either the
precontemplation or contemplation stage of change on the URICA upon entry to St.
Christopher’s. There are several possible explanations as to why smokers entering substance use
treatment may not be interested or ambivalent towards quitting smoking. In the overall sample,
continuous baseline URICA scores were positively correlated with health risk smoking
expectancies, indicating that participants in earlier stages of change tended to have lower health
risk smoking expectancies. Consistent with the current findings, past research has found
increased value of health to be predictive of successful cessation and health-related beliefs about
the consequences of smoking to be a strong predictor of motivation to quit smoking (Copeland et
al., 1995; McCaul et al., 2006; Rose et al., 1996). Interestingly, in the overall sample, continuous
baseline URICA scores were positively correlated with negative affect reduction smoking
expectancies, indicating that participants in earlier stages of changed tended to have lower
expectancies for smoking to reduce negative affect. Higher negative affect reduction and
negative reinforcement expectancies have been found to be predictive of post-cessation smoking
outcomes (Copeland et al., 1995; Wetter et al., 1994). Findings from the overall sample at
baseline indicate that it might be beneficial to provide stage-matched intervention (e.g.,
consciousness raising) for precontemplator and contemplator smokers, who were identified to
have lower health risk expectancies upon entering substance use treatment. The association
between lower negative affect reduction expectancies and earlier stages of change may also
provide opportunity for intervention. Smokers in early stages of change who do not have high

44

expectancies for smoking to reduce negative affect may be more receptive to learning coping
skills other than smoking to manage negative affect.
Participant Comparisons on Baseline Measures
A significant number of participants who completed the baseline assessment only were
excluded from analyses for aims 1, 2, and 3. Comparison analyses between participants who
completed the baseline assessment only and participants who completed the baseline assessment
and one or more follow-ups revealed one significant difference. Participants who completed the
baseline assessment and one or more follow-ups were identified as having significantly more
substance use disorders compared to participants who only completed baseline. This difference
in groups is somewhat intuitive, as it would be expected that those with a greater number of
substance use disorders would likely stay longer in substance use treatment. No other significant
differences were found between participants who completed the baseline assessment only and
those who completed baseline and one or more follow-up assessments on the baseline URICA,
SCQ-A Health Risks subscale, and SCQ-A Negative Affect Reduction subscale. Comparison
analyses provided evidence that those who completed the baseline assessment only and those
who completed the baseline assessment and one or more follow-up assessments were not
significantly different on baseline measures.
Main Outcomes
Aim 1
It was hypothesized in aim 1 that readiness to quit smoking would significantly increase
over time as an indirect effect of being in a long-term multimodal substance use treatment center.
However, this hypothesis was not supported as no significant difference was identified in
readiness to quit scores across assessments. At St. Christopher’s, patients learn behavioral and
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cognitive coping strategies to manage distress/ prevent relapse and learn about the negative
health consequences of substance abuse through psychoeducation. The apparent incongruity
between readiness to change substance use and readiness to change smoking behavior may be
explained by the substance use treatment context and culture. Individuals in early substance use
recovery report receiving advice to postpone smoking cessation attempts from a variety of
sources, including treatment center staff (Richter et al., 2002). It is therefore likely that even
smokers who are currently contemplating a cessation attempt would not progress in readiness to
quit smoking when they are being told cessation is inadvisable or even detrimental to their
substance use recovery. In past research, investigators have concluded that cessation
interventions for smokers in substance use treatment should include evidence-based information
regarding the myriad benefits of quitting smoking (Hendricks et al., 2014). The provision of this
information would be consistent with strategies such as ‘consciousness raising’ that are
suggested by J. O. Prochaska and DiClemente (1982) as stage-matched processes of change for
assisting precontemplators and contemplators to progress to the next stage of readiness or
motivation toward addictive behavior change. Within the current study, a majority of participants
who completed the baseline assessment and one or more follow-up assessments were in the
precontemplation or contemplation stage of change at baseline. Implementing consciousness
raising interventions, such as providing information about the causes, consequences, and
treatments related to smoking, for smokers in early stages of substance use treatment may be
beneficial for increasing readiness to quit smoking among this population (J. O. Prochaska et al.,
2015). Of course, there is also an extensive literature within addictive behavior change in which
motivation for change is addressed directly via motivational enhancement strategies and brief
motivational interventions (BMIs) in which the patient’s ambivalence toward change is expected
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and acknowledged, and the patient is provided with treatment information only upon request
(Miller & Rose, 2009). Research has shown that even providing brief advice about quitting
smoking increases motivation to quit among smokers in substance abuse treatment (Rohsenow et
al., 2014). In addition, pre-cessation motivational enhancement interventions have been found to
be useful for increasing interest in cessation programs in the context of substance abuse
treatment (Guydish et al., 2016). While interventions targeting motivation to quit smoking have
been found to be successful, most are implemented in the early stages of treatment and
motivation to quit is assessed in a similar time frame. The purpose of the current study was to
determine if readiness to quit smoking was malleable to attendance in long-term substance use
treatment, which was not supported. Interventions, such as BMIs or brief advice, may be
necessary to increase readiness to quit for smokers in substance use treatment. Future research
should focus efforts on tailoring proactive interventions to increase motivation to quit among
smokers in substance use treatment.
Aim 2
In relation to aim 2, it was hypothesized that smoking expectancies for health risks would
increase over time in substance use treatment. This hypothesis was based on the rationale that
psychoeducational components of substance use treatment programs regarding health risks
associated with substance use would generalize to patients’ smoking behavior as well, and this
would be reflected in increased health risk smoking expectancies over time. Contrary to
prediction, smoking expectancies for health risks significantly decreased over time in treatment.
The significant decrease was detected from the 30-day follow-up assessment to the 60-day
follow-up assessment. This unexpected finding may again be due to a lack of information, or
misinformation, that smokers receive in substance use treatment regarding the significant health
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risks associated with continued smoking and the substantial health improvements associated with
cessation. It is established in the literature that smokers with substance use comorbidities are
more likely to die from smoking-related illness than alcohol use and are at an increased risk for
mortality (Bandiera et al., 2015; Hser et al., 1994; Hurt et al., 1996). Although research on the
negative health consequences of smoking for those with substance use disorders has been
documented, this information may not be widely disseminated to staff or patients in substance
use treatment centers. A recent meta-analysis determined that among mental health professionals
(e.g., nurses, psychiatrists, and clinical psychologists) treating mental illness and substance use
disorders, almost half reported negative attitudes towards patients quitting smoking and
acceptance towards patients continuing to smoke (Sheals, Tombor, McNeill, & Shahab, 2016).
Interestingly, staff in substance use treatment centers have been found to be supportive of
cessation for patients as a result of health concerns (Richter et al., 2012). However, support of
cessation for patients due to health concerns among staff was partly accounted for by the belief
that smoking would exacerbate physiological conditions due to the use of other substances
(Richter et al., 2012). This provides further support of a potential gap in the information
disseminated to staff in substance use treatment centers regarding the significance of health
consequences of smoking within this population.
A potential avenue for future research is the development of interventions aimed at
educating mental health professionals and patients about the health consequences of smoking for
those in substance use treatment. In conclusion, it may be necessary to provide psychoeducation
regarding the health risks of smoking in substance use treatment to proactively address
misconceptions about the health consequences of smoking in this context. The decrease in health
risk expectancies over time offers support that smoking cessation services should be offered at
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treatment entry, or within the first 30 days, of substance use treatment as this is when health risk
expectancies were found to be the highest. Of note, the current study did not include a proactive
strategy in which smoking expectancies for health risks were specifically targeted for change. In
previous studies in which expectancies have been changed, they were targeted by a manipulation
in which information was presented to challenge the belief (e.g., there are effective alternatives
to smoking for reducing negative affect) or to augment existing beliefs (e.g., personalizing
smoking-related health risk information) to reinforce or increase health risk expectancies
(Copeland & Brandon, 2000). Future research should attempt to target the manipulation of health
risk smoking expectancies among smokers in substance use treatment.
Aim 3
In relation to Aim 3, it was hypothesized that negative affect reduction expectancies
would decrease over time in substance use treatment, as patients acquire alternative skills to
manage their negative moods. This hypothesis was supported, as there was a significant change
in negative affect reduction expectancies as a function of time or experience in substance use
treatment with lowest scores reported at the 60-day follow-up. It was anticipated that knowledge
from substance use treatment would generalize from substance use to smoking and that
knowledge would be sufficient (albeit indirect) to modify existing smoking expectancies for
negative affect reduction. The findings indicate that generalization did occur and was robust
enough to modify expectancies. St. Christopher’s multimodal program utilizes evidence-based
treatments, including dialectical behavior therapy skills and acceptance commitment therapy as
components of group and individual therapy (STC, 2016). A core component of both these
evidence-based treatments is mindfulness (Luoma, Hayes, & Walser, 2007; McKay, Wood, &
Brantley, 2019). Research has shown mindful attention to be negatively associated with negative
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affect among smokers (Paulus, Langdon, Wetter, & Zvolensky, 2018). Among those in cessation
programs, mindfulness has been associated with decreased expectancies of smoking to improve
mood (Spears et al., 2019). Although St. Christopher’s program is not entirely centered on the
use of mindfulness-based interventions in the treatment of substance use disorders, exposure to
such interventions may have generalized to smoking behavior and negative affect reduction
smoking expectancies. Findings suggest that it may be beneficial to provide cessation services
later in treatment when patients have established other coping strategies to manage negative
affect other than smoking. While treatment at St. Christopher’s incorporates interventions with
mindfulness components, future research should identify which specific coping skills to manage
negative affect developed in substance use treatment are linked to decreases in negative affect
reduction smoking expectancies. It may be the case that negative affect reduction smoking
expectancies can also be directly addressed and challenged in the context of substance use
treatment, in order to be significantly modified. For example, this might entail teaching patients
effective, alternate, concrete skills to manage negative mood (e.g., deep breathing, relaxation)
without resorting to smoking. Another strategy might be to challenge the validity of the belief by
developing competing cognitions, such as smoking is only a temporary fix for negative mood
and precludes the smoker from addressing the source of negative affect and potentially resolving
it. In previous studies, efforts to then personalize this information have been effective in
changing expectancies in the desired direction (Copeland & Brandon, 2000). Future research is
needed to determine if negative affect reduction expectancies can be challenged earlier on in
substance use treatment prior to 60 days.
Limitations
There were several notable limitations to the current study, such that the current findings
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should be interpreted with caution. First, the study was significantly underpowered. A power
analysis indicated that a sample of at least 46 participants completing all four assessments was
required to detect meaningful differences over time if they occurred. While the required sample
size was not met, the most conservative methods of handling missing data and performing
statistical analyses were implemented to prevent a Type I error occurrence. Out of the patients
admitted to St. Christopher’s during recruitment for the current study, only 38.6% completed the
baseline assessment and only 12.1% completed the baseline assessment and one or more followups. Mean substitution was implemented for 22.9% of data used in aims 1 and 2 and 20.8% of
data used in aim 3. The small sample used in aims 1, 2, and 3 was highly biased based on selfselection to stay in treatment and is most likely unrepresentative of smokers in substance use
treatment. It was identified that participants who completed the baseline assessment only and
those who completed the baseline and one or more follow-ups did not significantly differ on
baseline assessments and measures other than the number of substance use disorders present. It
was hypothesized that coping skills learned in substance use treatment would indirectly
generalize from substance use to smoking and this generalization would modify readiness to quit
smoking and negative affect reduction smoking expectancies. While negative affect reduction
smoking expectancies did decrease, potentially due to the acquisition of coping skills learned in
substance use treatment, the current study did not include a measure of coping skills. Future
research examining changes in readiness to quit smoking and negative affect reduction smoking
expectancies in the context of substance use treatment should include a measure of coping skills,
specifically, cognitive coping skills.
Overall changes to St. Christopher’s program contributed to difficulties with baseline and
follow-up data collection. Strategies were implemented in an effort to overcome these
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difficulties. Prior to beginning study recruitment, a presentation was provided to the staff at St.
Christopher’s, giving an overview of the study in an effort to build staff “buy-in” to assist with
data collection. In the early phases of study recruitment, several staff who had initially agreed to
assist in the collection of data were no longer working at St. Christopher’s or were working in
other positions within the facility. The reduction in staff assistance led to researchers spending
increased time attempting to locate participants for baseline assessments and follow-ups. There
was also a turnover in the retention of researchers who were recruiting participants and
administering baseline measures. The loss of researchers who were available to recruit and
administer baseline assessments led to a number of patients being ineligible to participate due to
seven days passing following their admittance to St. Christopher’s. As a result, other researchers
assisting with data collection were reassigned from collecting follow-up assessments to help with
baseline data collection. In the early phases of data collection, the treatment center changed
ownership and the head admissions coordinator resigned. The head admissions coordinator
would actively recruit patients and their families to commit to long-term treatment. Following his
resignation, a number of patients were found to be discharging treatment or transitioning to a
lower level of care earlier than usual.
Regarding issues with initial baseline recruitment, a number of patients reported not
being interested for several reasons. Throughout data collection, several patients reported
disinterest in participation due to the lack of incentives for the time it took to complete the four
assessments. Unfortunately, the inclusion of incentives posed ethical problems as participants
had to be smokers in order to be eligible for the study. Incentivizing participation could have
potentially led to patients at St. Christopher’s to begin smoking in order to receive incentives for
participation. During the middle phase of baseline data collection, it was determined that patients
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were reporting disinterest due to one participant advising others not to participate. The
participant was informing others that he believed the proposed sample size addressed in the
consent form was not adequately powered. The researcher collecting baseline data with this
participant discussed how the proposed sample size was determined. Another researcher met
with this participant at a later date to address that the sample size proposed in the consent form
was sufficient and to please refrain from discussing the study with other patients. Furthermore, to
circumvent this problem, the researcher collecting baseline data had staff at St. Christopher’s
bring patients to the office where data was collected. This change in procedure was done in lieu
of the researcher approaching patients in the milieu where they could be swayed by the opinions
of others. This seemed to reduce the influence of patients deterring potential participants. The
EMR charting system posed a problem in identifying newly admitted patients. The EMR
charting system labeled potential admits to St. Christopher’s the same as newly admitted
patients. As a result, there were several instances where the first author contacted one of the
study recruitment researchers to meet with a potential participant only to find out that the patient
had decided against coming to treatment. One of the researchers was actively working at St.
Christopher’s and became a point of contact to identify if a patient admitted into treatment and
could be contacted for recruitment.
The collection of follow-up assessments became significantly more difficult as data
collection proceeded. As mentioned earlier, the head admissions counselor and several staff
resigned from their positions throughout the early to middle stages of data collection and there
was a transition in ownership. Several of the staff who had initially agreed to assist researchers
with collecting follow-up data resigned or transitioned to other roles within the facility.
Researchers significantly increased the number of days and times they would attempt to follow-
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up with participants, which was not always successful. Identifying when a participant was
transitioning from one level of care to the next or discharging from the program was also
problematic for collecting follow-ups. This information was not available within the EMR
system. To address this problem, the researcher conducting follow-ups would call counselors or
staff days prior to the anticipated follow-up date to check the patient’s discharge/transition date
in an attempt to follow-up prior to discharge/ transition.
Finally, there were changes made to the medical and psychological intake evaluation
format and a transition to a new EMR charting system, which resulted in difficulty in collecting
some information for the Substance Use and Mental Health Form. The old EMR charting system
included a psychosocial assessment form that was used to develop items on the Substance Use
and Mental Health Form used in the current study. The new EMR charting system did not use
this same psychosocial assessment form. Information pertaining to previous mental health
treatment (other than substance use treatment) was not collected from the EMR charting system.
Within the psychiatrist and nurse practitioner notes in the EMR charting system, the explanation
for prescription of certain medications was not always clear. A number of medications have offlabel psychiatric uses, which made it unclear as to the reason for a prescription if not stated
explicitly. For example, gabapentin is prescribed as an adjunctive medication for alcohol use
disorder (Mason, Quello, & Shadan, 2018), yet it is also prescribed for seizures (Chadwick et al.,
1998) and diabetic neuropathy (Moore, Wiffen, Derry, & Rice, 2014). Due to the variability in
the explicit identification of the purpose of prescribed medication, this information was not
collected.
Conclusion
The results of the current study provide some insight into when smokers in substance use
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treatment may be most receptive to quitting smoking. It was determined that readiness to quit
smoking did not differ significantly by assessment, while negative affect reduction and health
risk smoking expectancies were both found to significantly decrease at the 60-day follow-up.
Results may seem contradictory as decreased negative affect reduction expectancies and
increased health risk expectancies have been found to be predictive of quit attempts and
successful cessation (Copeland et al., 1995). It may be beneficial to incorporate a manipulation
to challenge the beliefs or to augment existing beliefs related to health risk expectancies early on
in substance use treatment. Coping skills learned in substance use treatment may generalize to
smoking behavior and reduce negative affect reduction smoking expectancies as a patient
progresses through treatment. It may be especially important to include “pre-cessation readiness”
or motivational enhancement interventions to increase readiness to quit, which have been found
to be effective in prior literature (Guydish et al., 2016). Smokers in substance use treatment may
need more comprehensive multicomponent cessation interventions to elicit change. In
conclusion, it may be beneficial to provide cessation services between 30 and 60 days after
entering substance use treatment when there has been an opportunity to augment health risk
expectancies, provide pre-cessation motivational enhancement, and develop generalizable coping
skills to manage negative affect. Future studies of this type should address issues of external
validity and determine whether similar results are found in an adequately powered study, and
whether similar results would be obtained with a population with diverse demographics, as the
current study included only white males of a similar sociodemographic. Readiness to change and
smoking outcome expectancies are important factors in determining the optimal timing of
smoking cessation for smokers in substance use treatment, and further research is needed to
understand the role of these constructs within this context.

55

APPENDIX A. CONSENT FORM
Study Title:

Study Purpose
and Procedure:

Readiness to Change and Smoking Expectancies Among Adult Male Substance
Users Currently in Substance Use Treatment

The purpose of this research project is to identify changes in smoking
expectancies and readiness to quit smoking among adult males in substance use
treatment.
The study requires that you complete several surveys at different times,
including questionnaires regarding your use of cigarettes and other nicotine
products, expectancies related to smoking, and readiness to quit smoking as
well as a breathalyzer to determine current smoking. Additionally, information
from your St. Christopher’s chart will be used to gather pertinent information
regarding current and past psychological/medical history.

Risks/Discomforts:

Participation in the study is not known to cause any physical or psychological
risk or discomfort. Confidentiality is protected through use of a secured office
and locked filing cabinet where all completed study materials will be stored.
While every effort is being made to preserve confidentiality, there is always a
remote possibility that thieves could obtain your data. Again, this is very unlikely
given the multiple steps taken to assure that completed study measures kept
protected.

Benefits:

You will be contributing to our knowledge regarding smoking behavior among
those in substance use treatment.

Alternatives:

There are not alternatives for discontinuing participation. If you would like
resources regarding smoking cessation a list of referrals will be provided, but we
cannot attest to their efficacy.

Contact:

Amy L. Copeland, Ph.D., M.P., the Principal Investigator, can be reached at
copelan@lsu.edu. The Co-Investigator, Aaron Waters, M.A., can be reached at
awater7@lsu.edu

Performance Sites:

St. Christopher’s Addiction Wellness Center

Number of Participants: The maximum number of participants we plan to enroll is 200.
Subjects:
Inclusion:

Exclusion:

In order to participate in the study, participants must be 1) currently admitted
at St. Christopher’s, 2) be ≥ 18 years of age at the initial study visit, 3) be a
current smoker (e.g., report at least weekly smoking and provide an expired
carbon monoxide monitor reading of 8 > parts per million), 4) not mandated by
court system to attend substance use treatment, and 5) demonstrate a 7th
grade reading level or higher.
Participants will be excluded if any of the above criteria are not met.
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Privacy:

Results of this study may be published, but no names or identifying information
will be included in the publication. All personal information obtained in this
study will be kept confidential. Your responses will be labeled only with a study
identification number within an electronic database.

Financial Information: There is no financial compensation for participation in this study.
Right to Refuse:

Participation in this study is voluntary, and you may withdraw from the study at
any time without prejudicing your future relations with St. Christopher’s
Addiction Wellness Center.

Unforeseeable Risks: As with any study, confidentiality is a concern, however, confidentiality risk is
unlikely given the steps we have taken to ensure that participant identifying
information is kept confidential. Confidentiality is protected using locked filing
cabinets in secured rooms at Louisiana State University. Additionally, we have
obtained a Certificate of Confidentiality through the National Institutes of
Health.
Study-related illness
or injury:

Participants are instructed to seek necessary medical care from their physician
and contact the Principal Investigator, Dr. Amy Copeland (copelan@lsu.edu) in
the event of a study-related illness or injury.

New Findings:

Any significant new findings developed from the study data or independent
sources during the course of research which may influence your willingness to
continue in the study will be explained to you.

Withdrawal:

Participants may withdraw from the study at any time.

Removal:

Obvious disruption, harm or threat of harm to other study participants or
members of the research team will conclude in participant removal from the
study. Additionally, if a participant leaves treatment at St. Christopher’s they
will be removed.

Certificate of
Confidentiality:

To help us protect your privacy, we have obtained a Certificate of Confidentiality
from the National Institutes of Health. With this Certificate, the researchers
cannot be forced to disclose information that may identify you, even by a court
subpoena, in any federal, state, or local civil, criminal, administrative, legislative,
or other proceedings. The researchers will use the Certificate to resist any
demands for information that would identify you, except as explained below.
The Certificate cannot be used to resist a demand for information from
personnel of the United States Government that is used for auditing or
evaluation of federally funded projects or for information that must be
disclosed in order to meet the requirements of the federal Food and Drug
Administration (FDA).
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You should understand that a Certificate of Confidentiality does not prevent you
or a member of your family from voluntarily releasing information about
yourself or your involvement in this research. If an insurer, employer, or other
person obtains your written consent to receive research information, then the
researchers may not use the Certificate to withhold that information.
The Certificate of Confidentiality does not prevent the researchers from
disclosing voluntarily, without your consent, information that would identify you
as a participant in the research project under the following circumstances:
reporting of child abuse and intent to hurt self or others.

Signatures:

“The study has been discussed with me and all my questions have been
answered. I may direct additional questions regarding study specifics to the
investigators. For injury or illness, call your physician, or the Student Health
Center if you are an LSU student. If I have questions about subject’s rights or
other concerns, I can contact Dennis Landin, Chairman, LSU Institutional Review
Board, (225) 578-8692, irb@lsu.edu, or www.lsu.edu/research. I agree to
participate in the study described above and acknowledge the researcher’s
obligation to provide me with a copy of this consent form if signed by me.”

Subject Signature: ____________________________ Date: _________________

Illiterate subjects:

When ANY subjects are likely to be illiterate, the "reader statement" and
signature line below are included.)
“The study subject has indicated to me that he/she is unable to read. I certify
that I read this consent form to the subject and explained by completing the
signature line above, the subject agreed to participate.”

Signature of Reader: _____________________________ Date: _______________
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For research involving the collection of identifiable private information or identifiable
biospecimens one of the following must be listed on the consent form:
Identifiers might be removed from the identifiable private information or identifiable
biospecimens. After removal, the information or biospecimens may be used for future research
studies or distributed to another investigator for future research studies without additional
informed consent.

Yes, I give permission________________________________________________
Signature

No, I do not give permission___________________________________________
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APPENDIX B. HIPAA AGREEMENT FORM
Authorization to Use or Disclose (Release) Health Information that Identifies You for a Research
Study
If you sign this document, you give permission to St. Christopher’s Addiction Wellness Center (St.
Christopher’s) to use or disclose (release) your health information that identifies you for the research
study described here:
The current study titled, Readiness to Change and Smoking Expectancies Among Adult Male
Substance Users Currently in Substance Use Treatment, is being conducted at St. Christopher’s. The
study aims to identify changes in smoking expectancies and readiness to quit smoking among adult males
in substance use treatment.
The health information that we may use or disclose (release) for this research includes:
The current study will use information pertaining to a participant’s substance use and mental
health history that will be collected from medical chart records through St. Christopher’s online charting
system.
The health information listed above may be used by and/or disclosed (released) to: The Copeland
Smoking and Substance Use Clinical Research Lab.
St. Christopher’s is required by law to protect your health information. By signing this document, you
authorize St. Christopher’s to use and/or disclose (release) your health information for this research.
Those persons who receive your health information may not be required by Federal privacy laws (such as
the Privacy Rule) to protect it and may share your information with others without your permission, if
permitted by laws governing them.
Please note that St. Christopher’s may not condition (withhold or refuse) treating you on whether you sign
this Authorization.
Please note that you may change your mind and revoke (take back) this Authorization at any time, except
to the extent that St. Christopher’s has already acted based on this Authorization. To revoke this
Authorization, you must write to:
St. Christopher's Addiction Wellness Center
150 Cora Drive
Baton Rouge, LA 70815
(225) 387-1611
This Authorization does not have an expiration date.
_________________________
Signature of participant or participant’s
personal representative

_________________________
Date

_________________________
Printed name of participant or
participant’s personal representative

_________________________
If applicable, a description of the
personal representative’s authority to
sign for the participant
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APPENDIX C. THE RAPID ESTIMATE OF ADULT LITERACY IN MEDICINE —
SHORT FORM

Patient ID #: ________________________

Date: ___________

Behavior _____
Exercise _____
Menopause _____
Rectal _____
Antibiotics _____
Anemia _____
Jaundice _____

TOTAL SCORE ______
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APPENDIX D. DEMOGRAPHIC AND SMOKING QUESTIONNAIRE
TO BE COMPLETED BY RESEARCHER
Date:
Participant ID#:
Assessment #:
Treatment (Primary, EC, IOP, 12-Step):
Carbon Monoxide Monitor Reading:
TO BE COMPLETED BY PARTICIPANT
1.

Age: ________

2. Sex (circle one)

MALE

3. Highest level of education completed (in years): __________
4. Annual household income: __________
5. What is your current employment status? (circle one)
a. Unemployed
b. Part-time employed
c. Full-time employed
6. With which ethnic/ racial group do you most identify yourself? (circle one)
a. Caucasian
b. African-American
c. Asian
d. Hispanic
e. Other
7. How often do you smoke? (circle one)
a. Daily
b. Weekly
c. Monthly
d. Yearly
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FEMALE

8. Do you smoke cigarettes every day? (circle one)
a. Yes
b. No
(If YES, please answer question #9-10.
If NO, please skip to #11)
9. How many years have you been smoking daily? __________
10. How many cigarettes per day do you smoke on average? __________
11. How many serious attempts (at least 24 hours) have you made to quit smoking PRIOR to
entering St. Christopher’s substance use treatment center? ____________
12. How many serious attempts (at least 24 hours) have you made to quit smoking SINCE you
have been in substance use treatment at St. Christopher’s? ____________
13. Do you use any type of electronic cigarette or vape? (circle one)
a. Yes
b. No
14. Do you use any other types of smokeless tobacco (e.g., chewing tobacco)? (circle one)
a. Yes
b. No
15. How are you currently paying for substance use treatment at St. Christopher’s? (circle one)
a. Medicaid/Medicare
b. Private health insurance
c. Out of pocket
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APPENDIX E. SUBSTANCE USE AND MENTAL HEALTH FORM
TO BE TAKEN FROM PSYCHOSOCIAL ASSESSMENT IN PATIENT CHART:
1.When was last use of any substance? __________
2. What was last substance used prior to entering treatment? ___________
3. What is substance of choice? __________
4. Age of first use and substance used: ___________________
5. Number of treatment centers attended: __________
6. Longest period of completed abstinence from substances: __________
7. Substances used during month prior to admission to substance use treatment (circle below):
a. Alcohol
b. Cannabis
c. Cocaine (crack)
d. Cocaine (powder)
e. Methamphetamine

f. Amphetamines
g. Opiates
h. Benzodiazepines
i. Inhalants
k. steroids

8. Current suicidal ideation?

YES

NO

9. Past suicidal ideation?

YES

NO

j. Hallucinogens
k. Ecstasy
l. Bath salts

10. Mental health treatment
Date: __________

Condition being treated: ___________________

Date: __________

Condition being treated: ___________________

Date: __________

Condition being treated: ___________________

Date: __________

Condition being treated: ___________________

Date: __________

Condition being treated: ___________________

Date: __________

Condition being treated: ___________________
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11. Medications
Current medication: _________________
Current medication: _________________
Current medication: _________________
Current medication: _________________
12. DSM – 5 Criteria for Substances of Choice
Substance use disorder: ____________________

Severity: __________________

Substance use disorder: ____________________

Severity: __________________

TO BE TAKEN FROM PSYCHIATRIST OR NURSE PRACTITIONER NOTE IN
PATIENT CHART:
Substance use disorders present:
Substance use disorder: ____________________

Severity: __________________

Substance use disorder: ____________________

Severity: __________________

Substance use disorder: ____________________

Severity: __________________

Substance use disorder: ____________________

Severity: __________________

Other psychological disorders present:
Disorder: ____________________ Severity: __________________
Disorder: ____________________ Severity: __________________
Disorder: ____________________ Severity: __________________
Disorder: ____________________ Severity: __________________
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APPENDIX F. UNIVERSITY OF RHODE ISLAND STAGES OF CHANGE
ASSESSMENT
Please indicate the extent to which you tend to agree or disagree with each statement. In each
case, make your choice in terms of how you feel right now, not what you have felt in the past or
would like to feel.
For all the statements that refer to your “problem”, answer in terms of your smoking. And “here”
refers to the place of treatment.
There are FIVE possible responses to each of the items in the questionnaire:
1 = Strongly Disagree 2 = Disagree 3 = Undecided 4 = Agree 5 = Strongly Agree
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.

As far as I’m concerned, I don’t have any problems that need
changing.
I think I might be ready for some self-improvement.
I am doing something about the problems that had been bothering
me.
It might be worthwhile to work on my problem.
I’m not the problem one. It doesn’t make much sense for me to be
here.
It worries me that I might slip back on a problem I have already
changed, so I am here to seek help.
I am finally doing some work on my problem.
I’ve been thinking that I might want to change something about
myself.
I have been successful in working on my problem but I’m not sure I
can keep up the effort on my own.
At times my problem is difficult, but I’m working on it.
Being here is pretty much a waste of time for me because the
problem doesn’t have to do with me.
I’m hoping this place will help me to better understand myself.
I guess I have faults, but there’s nothing that I really need to change.
I am really working hard to change.
I have a problem and I really think I should work at it.
I’m not following through with what I had already changed as well
as I had hoped, and I’m here to prevent a relapse of the problem.
Even though I’m not always successful in changing, I am at least
working on my problem.
I thought once I had resolved my problem I would be free of it, but
sometimes I still find myself struggling with it.
I wish I had more ideas on how to solve the problem.
I have started working on my problems but I would like help.
Maybe this place will be able to help me.

66

_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____

22. I may need a boost right now to help me maintain the changes I’ve
already made.
23. I may be part of the problem, but I don’t really think I am.
24. I hope that someone here will have some good advice for me.
25. Anyone can talk about changing; I’m actually doing something about
it.
26. All this talk about psychology is boring. Why can’t people just forget
about their problems?
27. I’m here to prevent myself from having a relapse of my problem.
28. It is frustrating, but I feel I might be having a recurrence of a
problem I thought I had resolved.
29. I have worries but so does the next guy. Why spend time thinking
about them?
30. I am actively working on my problem.
31. I would rather cope with my faults than try to change them.
32. After all I had done to try to change my problem, every now and
again it comes back to haunt me.
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_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____

APPENDIX G. SMOKING CONSEQUENCES QUESTIONNAIRE – ADULT
Instructions: This questionnaire is designed to assess beliefs people have about the consequences of smoking a
cigarette. We are interested in your general expectations about the consequences of your smoking. Below is a list
of statements. Each statement contains a possible consequence of smoking. For each of the statements listed below,
please rate how LIKELY or UNLIKELY you believe each consequence is for you when you smoke. If the
consequence seems LIKELY to you, circle a number from 5-9. That is, if you believe that a consequence would
never happen, circle 0; if you believe a consequence would happen every time you smoke, circle 9. Use the guide
below to aid you further. For example, if a consequence seems completely likely to you, you would circle 9. If it
seems a little unlikely to you, you would circle 4.
0
1
2
3
4
5
6
7
8
9
Completely
Very
A little A little
Very
Completely
Extremely
Somewhat
Somewhat
Extremely
-----------------UNLIKELY------------------------X-----------------------LIKELY------------------
UNLIKELY
0 1

1. Cigarettes taste good.

LIKELY
2

3

4

5

6

7

8

9

2. Smoking controls my appetite.

0

1

2

3

4

5

6

7

8

9

3. My throat burns after smoking.

0

1

2

3

4

5

6

7

8

9

4. Cigarettes help me deal with anxiety or worry.

0

1

2

3

4

5

6

7

8

9

5. Nicotine “fits” can be controlled by smoking.

0

1

2

3

4

5

6

7

8

9

6. When I’m angry, a cigarette can calm me down.

0

1

2

3

4

5

6

7

8

9

7. When I’m alone, a cigarette can help me pass the time.

0

1

2

3

4

5

6

7

8

9

8. I become more addicted the more I smoke.

0

1

2

3

4

5

6

7

8

9

9. If I’m tense, a cigarette helps me to relax.

0

1

2

3

4

5

6

7

8

9

10. Cigarettes keep me from overeating.

0

1

2

3

4

5

6

7

8

9

11. Smoking a cigarette energizes me.

0

1

2

3

4

5

6

7

8

9

12. Cigarettes help me deal with anger.

0

1

2

3

4

5

6

7

8

9

13. Smoking calms me down when I feel nervous.

0

1

2

3

4

5

6

7

8

9

14. Cigarettes make my lungs hurt.

0

1

2

3

4

5

6

7

8

9

15. I feel like I do a better job when I am smoking.

0

1

2

3

4

5

6

7

8

9

16. A cigarette can give me energy when I’m bored and tired.

0

1

2

3

4

5

6

7

8

9

17. Cigarettes can really make me feel good.

0

1

2

3

4

5

6

7

8

9

18. When I’m feeling happy, smoking helps me keep that feeling.

0

1

2

3

4

5

6

7

8

9

19. I will enjoy the flavor of a cigarette.

0

1

2

3

4

5

6

7

8

9

20. If I have nothing to do, a smoke can help kill time.

0

1

2

3

4

5

6

7

8

9

21. I will enjoy feeling a cigarette on my tongue and lips.

0

1

2

3

4

5

6

7

8

9

22. Smoking will satisfy my nicotine cravings.

0

1

2

3

4

5

6

7

8

9

23. I feel like part of a group when I’m around other smokers.

0

1

2

3

4

5

6

7

8

9

24. Smoking makes me seem less attractive.

0

1

2

3

4

5

6

7

8

9

25. By smoking, I risk heart disease and lung cancer.

0

1

2

3

4

5

6

7

8

9
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26. Smoking makes me enjoy people more.

0

1

2

3

4

5

6

7

8

9

27. Cigarettes help me reduce or handle tension.

0

1

2

3

4

5

6

7

8

9

28. I feel better physically after having a cigarette.

0

1

2

3

4

5

6

7

8

9

29. I enjoy parties more when I am smoking.

0

1

2

3

4

5

6

7

8

9

30. People think less of me if they see me smoking.

0

1

2

3

4

5

6

7

8

9

31. A cigarette can satisfy my urge to smoke.

0

1

2

3

4

5

6

7

8

9

32. Just handling a cigarette is pleasurable.

0

1

2

3

4

5

6

7

8

9

33. If I’m feeling irritable, a smoke will help me relax.

0

1

2

3

4

5

6

7

8

9

34. Smoking irritates my mouth and throat.

0

1

2

3

4

5

6

7

8

9

35. When I feel bored and tired, a cigarette can really help.

0

1

2

3

4

5

6

7

8

9

36. I will become more dependent on nicotine if I continue smoking.

0

1

2

3

4

5

6

7

8

9

37. Smoking helps me control my weight.

0

1

2

3

4

5

6

7

8

9

38. When I’m upset with someone, a cigarette helps me cope.

0

1

2

3

4

5

6

7

8

9

39. The more I smoke, the more I risk my health.

0

1

2

3

4

5

6

7

8

9

40. Cigarettes keep me from eating more than I should.

0

1

2

3

4

5

6

7

8

9

41. I enjoy the steps I take to light up.

0

1

2

3

4

5

6

7

8

9

42. Conversations seem more special if we are all smoking.

0

1

2

3

4

5

6

7

8

9

43. I look ridiculous while smoking.

0

1

2

3

4

5

6

7

8

9

44. Smoking keeps my weight down.

0

1

2

3

4

5

6

7

8

9

45. I like the way a cigarette makes me feel physically.

0

1

2

3

4

5

6

7

8

9

46. Smoking is hazardous to my health.

0

1

2

3

4

5

6

7

8

9

47. I enjoy feeling the smoke hit my mouth and the back of my throat.

0

1

2

3

4

5

6

7

8

9

48. When I smoke, the taste is pleasant.

0

1

2

3

4

5

6

7

8

9

49. I like to watch the smoke from my cigarette.

0

1

2

3

4

5

6

7

8

9

50. When I am worrying about something, a cigarette is helpful.

0

1

2

3

4

5

6
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51. Smoking temporarily reduces those repeated urges for cigarettes.
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52. I enjoy the taste sensations while smoking.
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53. I feel more at ease with other people if I have a cigarette.

0
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54. Cigarettes are good for dealing with boredom.

0
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9

55. Smoking is taking years off my life.

0
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5
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7

8

9
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APPENDIX H. FAGERSTRÖM TEST FOR NICOTINE DEPENDENCE
1. How soon after you wake up do you smoke your first cigarette?
a. Within 5 minutes
b. 6-30 minutes
c. 31-60 minutes
d. After 60 minutes
2. Do you find it difficult to refrain from smoking in places where it is forbidden e.g., in church,
at the library, in the cinema, etc.?
a. Yes
b. No
3. Which cigarette would you hate most to give up?
a. The first one in the morning
b. All others
4. How many cigarettes do you smoke a day?
a. 10 or less
b. 11-20
c. 21-30
d. 31 or more
5. Do you smoke more frequently during the first hours after waking than during the rest of the
day?
a. Yes
b. No
6. Do you smoke if you are so ill that you are in bed most of the day?
a. Yes
b. No

70

APPENDIX I. IRB APPROVAL
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